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Mrs. A.B. is a 68 year old woman who received a primary total hip arthroplasty (THA) 
for a painful osteoarthritis of her hip 14 years ago. She was very satisfied with the hip 
replacement; the pain in her hip had disappeared and she regained the ability to walk and 
cycle again, two of her favorite hobbies. However, 3 years ago the pain in her hip returned 
and physical activity became increasingly difficult again. Finally, her discomfort when 
walking or cycling forced her to visit her orthopedic surgeon. An X-ray revealed a loose 
prosthesis with bone loss around the acetabulum and proximal femur. The orthopedic 
surgeon and the patient decided for a hip revision surgery. During the surgery, both the 
acetabular and femur component of the hip prosthesis were replaced by a new implant 
and the bone loss was restored with bone from a bone bank. The surgery lasted 4 hours 
and had a great impact on Mrs. A.B. During the surgery she had 1.5 liters of blood 
loss. Postoperatively she developed a wound infection for which she had to stay in the 
hospital for 6 more weeks. She was treated with intravenous antibiotics and surgical 
debridement of the infected area. Moreover, rehabilitation for this second surgery was 
much longer when compared to the first hip replacement. At this moment, 1 year after 
the hip revision surgery, she is satisfied with the outcome and will be monitored by her 
orthopedic surgeon yearly.
Osteoarthritis and total hip arthroplasty
Osteoarthritis refers to a clinical syndrome of joint pain accompanied by varying degrees 
of functional limitation and reduced quality of life [1]. It is characterized by progressive 
pathological changes of the articular cartilage [1, 2]. These changes include localized loss 
of cartilage and remodeling of subchondral and adjacent bone with new bone formation 
(osteophyte) at the joint margins. The cause of this disorder is not completely understood, 
but forces that place high biomechanical stresses on the joints (bearing weight, postural 
or orthopedic abnormalities) or injuries that cause chronic irritation of the bone are 
thought to interact with biochemical and genetic factors to contribute to osteoarthritis 
[1, 2]. Symptoms of osteoarthritis include pain, reduced function, stiffness, instability 
and disability. Osteoarthritis is the most common disease of joints and is responsible for 
considerable morbidity [1]. It affects about 8 million people in the United Kingdom and 
nearly 27 million people in the United States. In the Netherlands, an estimated 657,000 
people have osteoarthritis (2007, osteoarthritis of the hip or other joints) [3]. However, 
the exact incidence and prevalence of osteoarthritis is difficult to determine because 
the early structural changes of the articular cartilage associated with osteoarthritis are 
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preceding clinical symptoms and thus are not detected in most cases in an early stage 
of the disease [1, 2].
The first attempts to treat patients with osteoarthritis of the hip surgically, by replacing 
the diseased joint by a THA, were performed more than 100 years ago. Since the 1960s, 
success rates of the surgical treatment of osteoarthritis of the hip joint increased greatly 
[2, 4, 5]. Nowadays, yearly about 25,000 THAs are performed in The Netherlands and 
more than 500,000 THA procedures are done every year in the UK and USA [4]. Results of 
these THA procedures are excellent; clinical outcomes show greater than 95% survivorship 
at 10-year follow up and greater than 80% at 25-year follow up [4]. Quality of life of the 
patient with osteoarthritis of the hip increases greatly after this procedure. As a result of 
the success and the ageing population, the number of THA procedures has increased the 
last decades. Also, this procedure is performed in increasingly younger and more active 
patients which also leads to increased numbers of THAs annually [6]. 
Hip revision arthroplasty and bone impaction grafting
Mechanical loosening is one of the most common causes of failure of a primary THA 
[6] and occurs secondary to a chronic, granulomatous, inflammatory response that is 
stimulated and maintained by implant-derived wear particles [7, 8]. This process is 
complex and involves the interactions of numerous cytokines, chemokines and growth 
factors [9]. These affect the osteoclasts at distinct stages of their development and 
imbalance between osteoclast and osteoblast activity may arise. This might lead to a 
localized or systemic reduction in bone mass [9]. A classification of loss of bone stock 
around the implant is proposed by Paprosky et al. [10] (Figure 1.1). After failure of a 
primary THA, a more challenging and costly hip revision surgery is needed, mainly due 
to management of the bone stock loss. In the Netherlands, 11,283 patients received a hip 
revision surgery from 2007 to 2011 [11]. Patients undergoing hip revision surgery have 
a longer hospital stay, an increased risk of complications and costs are at least 35% more 
when compared to primary hip arthroplasty [12]. Survival rates of revision THAs are 
good, but the longevity is generally lower than that of primary THAs [13]. Survival rates 
in literature differ from 35% to 100% at 10 years [13-16]. These large differences can be 
explained by the heterogeneity of revision surgery.  
One of the techniques to restore the bone stock around the implant is bone impaction 
grafting (BIG, Figure 1.2) [14]. With BIG, first, the defects in acetabulum and femur can 
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be restored with metal meshes in order to recreate a contained defect. Next, these defects 
are filled with tightly impacted morselized allograft cancellous bone chips in combination 
with a cemented new prosthesis. The allograft bone serves as a scaffold; new blood vessels 
and woven bone can grow into the allograft bone and during this process the allograft 
bone is resorbed by osteoclasts. The remodelling of newly formed immature bone into 
its characteristic mature bony structure will lead to a biological repair of the defect [17]. 
From biopsies taken from the acetabular component of patients who underwent hip 
revision surgery with bone impaction grafting, it is clear that the allograft bone will be 
almost completely remodeled and replaced by new bone [18], although this might take 
several months or even years [19]. 
BIG for bone loss in hip revision cases has been used with satisfactory results in clinical 
practice for acetabular revisions since 1979 and for femoral defects in revision surgery 
Figure 1.1 Illustration depicting the Paprosky acetabular defect classification system, 
obtained from Weeden et al. [107].
Type 1: Mild bone loss. Undistorted rim
Type 2: Intermediate bone loss. Distorted but intact rim, will support cup.
Type 3: Severe bone loss. Non-supportive rim.  
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since 1987 [14, 20-26]. Survival rates between 52% and 94% have been reported up to 28 
years after the surgery with BIG [14, 24, 27-32]. BIG is a frequently applied procedure 
to restore bone stock losses. Lie et al. [13] evaluated hip revision surgeries from 1987 
to 2003 in Norway and found that in 29% of all acetabular revisions bone graft is used 
and in 11% BIG is applied. For femoral revisions these percentages are 28% and 19%, 
respectively.
This thesis will focus on BIG and how in the future the results of hip revision surgery 
with BIG could be improved by treatment of the allograft bone chips which are used 
during impaction grafting.  
Figure 1.2 Impaction grafting technique, obtained from Schreurs et al. [23].
A. Hip with an acetabular defect after removal of the failed cup
B. The medial wall defect is closed by a metal mesh that can be fixed with screws
C. The cavitary defect is filled layer by layer with bone graft chips
D. These bone graft chips are impacted
E. After impaction, the impactors can be removed without collapse of the construction
F. Cement is injected and pressurized to facilitate cement penetration into the graft
G. Hip after cup insertion
 
12
Review of literature and aim of this thesisChapter 1
Allograft bone and bone banking 
Autograft bone is the best material to restore bony defects [33]. Autograft bone has 
a major advantage in that it provides not only a three-dimensional structure of bone 
(osteoconduction), but also osteoblasts that will form new bone (osteogenesis) [33]. 
Moreover, autograft bone will trigger the formation of new osteoblasts, theoretically 
promoting faster integration of the graft (osteo-induction). However, donor site 
morbidity and limited availability are the major drawbacks in the use of autograft 
bone in reconstructive surgery [18]. Therefore, bone graft substitutes or allograft bone 
might be used during orthopedic surgeries for the reconstruction of bone defects. An 
increasing number of bone substitutes is available on the market. Examples of bone 
graft substitutes are tricalcium phosphate, calcium sulphate and hydroxyapatite. These 
substitutes are osteoconductive materials and have the advantages of being totally free 
of potentially infectious diseases and do not cause an immune-rejection reaction [34]. 
Contrary, allograft bone might transmit infectious diseases, although this is very rare 
[33]. Allograft bone is osteoconductive but might also release growth factors which 
could stimulate some degree of osteo-induction [18, 35]. Allograft bone for bone 
transplantations has been used for over 130 years; the first known bone transplant in 
humans has been performed in 1878 [36]. In the 1950s the first tissue bank was founded, 
the Navy Tissue Bank in Bethesda, Maryland [37]. A system was created in which cadaver 
donation was performed in an operating room which was dedicated solely to tissue 
procurement, which increased the availability of allograft tissue. In The Netherlands, 
a central bone bank was established in 1988 [38]. With increasing amounts of surgical 
procedures, the demand for allograft bone also increased [36]. After 1980, emphasis 
was placed on safety and prevention of disease transmission, since it was clear from 
several cases that allograft bone might transmit blood-borne diseases [36]. Last decades, 
first American guidelines on donor selection, tissue quarantine and tissue processing 
were developed [39] followed by the development of European guidelines [40]. With 
stringent donor selection and improved screening methods, the risk of viral transmission 
is reduced [33]. 
For BIG, mostly femoral heads from living donors are used. These femoral heads can be 
processed or used fresh frozen. Processing includes several methods to clean the allograft 
and remove at least fat, blood and marrow and wash out immunogenic factors [41]. No 
research has been done on the differences between these fresh frozen and processed 
allografts [41]. However, it is clear that rinsing the allograft before use improves the 
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incorporation of the allograft tissue [42]. Improvement of the incorporation of allograft 
bone might reduce the risk of failure. 
Loosening and hip revision surgery
Nineteen to thirty percent of all failures after revision surgery are caused by loosening 
of the prosthesis [6, 15, 43, 44]. After hip revision surgery with BIG, remodeling of the 
allograft bone occurs by a process called creeping substitution. Creeping substitution or 
“schleichender ersatz” as it was first named by Axhausen in 1907 is an ongoing process of 
bone resorption and bone deposition in the skeleton throughout life, refreshing the tissue, 
adapting to mechanical stress or metabolic changes [45]. When allograft or autograft 
bone tissue is being used, this process also takes place, however the coupling between 
osteoblast and osteoclast function is less organized. Therefore it might lead to faster 
resorption in relation to bone deposition. In the case of BIG this may lead to destabilization 
of the implant. This mechanical weakness might result in loosening of the prosthesis. 
To optimize the balance between bone resorption and bone formation bisphosphonates 
might be used. Bisphosphonates are used for a variety of bone diseases in which excessive 
osteoclast activity is an important feature, including Paget’s disease, bone tumors and, of 
course, osteoporosis [46]. Bisphosphonates were first synthesized in the 1800s and used 
as corrosion inhibitors, and in the textile, fertilizer and oil industry as ‘water softeners’ 
[46]. Their medical uses were not recognized until the 1960s. Fleisch, Russell and co-
workers discovered that bisphosphonates have a high affinity for bone mineral. Using 
bisphosphonates, they were able to prevent calcification of many soft tissues as well as 
originally calcified tissues as bone and cartilage [47, 48] . In 1969 the first studies of the 
use of bisphosphonates in humans were published [46, 48]. Bisphosphonates inhibit bone 
resorption by inducing apoptosis of the osteoclasts [49, 50]. 
However, systemic administration of bisphosphonates after hip revision arthroplasty 
with BIG has the disadvantages that the allograft bone will only be treated once it has 
been revascularised [51]. Furthermore, blocking necrotic bone resorption, as in the 
case of a bone graft, may require higher local concentrations, which may be difficult 
to achieve with systemic treatment [52]. Such problems would be solved if the graft 
could be treated before implantation. Several studies have been performed on the local 
application of bisphosphonates, however results vary greatly [53-56]. An overview of 
all studies combining bisphosphonates with allograft bone is presented in chapter 2 
of this thesis. To investigate whether an optimal dose regarding bone resorption and 
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bone formation after local application of bisphosphonates with allograft bone exists, an 
animal study was conducted. Moreover, we questioned whether it is possible to stimulate 
bone formation with the addition of demineralized bone matrix (DBM) to bone chips 
impregnated with bisphosphonate. DBM is a product of processed allograft bone and 
contains collagen, proteins and growth factors [57]. Demineralization of bone might 
facilitate the release of growth factors which could increase the bioactivity of the graft 
and increase new bone formation and thus the amount of new bone [58, 59] which might 
be of importance during the early critical period after surgery with BIG. Results of this 
study are presented in chapter 3.
Infection and hip revision surgery
When joint prosthetic surgery started on a larger scale in the 1960s, infection rates between 
5 and 10% were reported for hip as well as for knee replacement [60, 61]. In 1964, Sir 
John Charnley managed to reduce this percentage by reducing the bacterial content of 
the air by operating inside a filtered-air enclosure [60]. The numbers of infections have 
further been reduced by improvements in operating techniques, antibiotics, improvements 
in operating theatre circumstances, stricter pre- and perioperative routines avoiding 
operating on patients with active infection (i.e. urinary tract infection) and shorter 
preoperative hospitalization [61]. Nowadays, infections occur in approximately 0.5 to 
3% of all primary THAs and after revision THA, these percentages are higher and range 
from 4 to 6% [4, 15, 43, 44]. 
Infection is one of the most common causes of failure after a hip revision surgery, and 
accounts for 12–30% of all failures [6, 13, 15, 43, 44]. Infection is a potentially devastating 
complication; patients may require further surgery, additional nursing care and in extreme 
cases it is followed by the death of the patient. Moreover, it might result in a reduced 
quality of life and greater physical limitations [62, 63]. Hospital stay increases greatly 
and some patients are hospitalized for months. Furthermore, the costs of hospitalisation 
of an infected patient are about 2.5 times higher than the costs of hospitalisation of an 
uninfected patient (results obtained from RdGG hospital, Delft, The Netherlands, 2012). 
Reducing the risk of infection is a major challenge that deserves continued attention. It 
is important to understand etiology and risk factors for infection to be able to prevent 
and reduce infection rates. Periprosthetic joint infections occur rarely and risk factors 
for infection after total joint arthroplasty remain subject of debate [64]. However, it can 
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be stated that the etiology of infection is multifactorial and can be divided in three major 
areas: the surgical technique, the surgical environment and the patient [65]. 
The surgical technique
The use of allograft bone chips for BIG introduces a potential source of infection. In 
most cases, the allograft bone which is used for BIG, is prepared in the operating theatre 
during surgery just prior to use. The preparation of bone chips in the operation room 
takes about ten minutes, it necessitates the use of special instrument such as a bone mill 
and due to the limited area in a down flow plenum system, an enclosed space inside the 
operating theatre with laminar air flow, the preparation of bone chips often takes place 
outside the plenum. However, the processing of these femoral heads can also be done in 
the laboratory of a bone bank. In that case the femoral heads are prepared in a top-class 
level clean room with optimal controlled environmental conditions and no surgery time 
is needed for preparation. Therefore, in chapter 4 we investigated the potential benefit in 
terms of lower contamination rates of the use of pre-processed bone chips when compared 
to bone chips prepared intra-operatively.
Relatively small numbers of bacteria of low virulence are able to establish infection in 
the presence of the surgical implant [66-69]. These infections are usually treated by 
administering high dose antibiotics systematically for prolonged periods of time. The 
effect of systemic administrated antibiotics as a profylaxis against infection, has been 
studied by Lidwell et al. [70]. A positive effect with regard to infection has been shown 
in that study. However, the surgery creates a vascular compromised wound bed where 
local circulation is disrupted. If infection arises, poorly vascularized tissue is less likely 
to sustain adequate antibiotics levels when antibiotics are administered systemically [71]. 
In addition, the formation of a biofilm on the surface of the implant renders systemic 
antibiotics less effective [69]. As a prophylaxis against these infections, bone cements 
containing antibiotics were developed. These cements may serve as a drug delivery 
system as they make it possible to achieve higher local drug concentrations. However, 
controversy exists on the efficacy of the antibiotic-containing cements [72]. Probably 
90% of the antibiotics contained in the cement is never released [73]. Only when cracks 
are formed in the cement layer, a small sub-inhibitory amount of antibiotics will be 
released into the surrounding tissue. This release can continue for years, potentially 
inducing resistance [73]. 
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Several studies have shown that the allograft bone, used for BIG, can act as a carrier for 
antibiotics, either by impregnating the bone grafts with various antibiotic solutions [74-
78], or by mixing them with antibiotic powders [79, 80]. These studies showed that bone 
impregnated with antibiotics can be used effectively as prophylaxis against infections. 
However, not much is known about the local release of the antibiotics from the allograft 
bone. Therefore, in chapter 5 of this thesis, we investigated whether it was possible to 
develop a standardized bone bank product in which the amount of antibiotics present on 
the bone chips, and therefore the amount of antibiotics released locally from the bone, 
are known. In addition, we investigated if storage of antibiotics and antibiotic-loaded 
bone grafts at different temperatures affects their activity. 
In chapter 3, a study is presented in which we investigated whether local use of antibiotics 
has influence on bone formation and graft remodeling in a goat model. 
The surgical environment
Since Charnley managed to reduce infection rates after total joint arthroplasties by 
operating inside a filtered-air enclosure, several improvements in surgical environment 
have been done. Enhancing air quality by reducing airborne contamination has been 
shown to be of great importance, especially in relation to implant surgery. An important 
development is the introduction of laminar air flow (LAF) at the operating room [81]. 
Lidwell et al. [70] concluded in their landmark study that there is a strong relation 
between the level of bacterial air contamination and the prevalence of deep surgical site 
infection. Prosthesis infection may occur post-operatively, but is often caused by bacterial 
contamination intra-operatively [82]. Transfer of bacteria from the skin of the patient or 
theatre personnel through instruments and other materials to the wound area, might result 
in intra-operative contamination [83] and as much as 70% of all air-borne bacteria reach 
the wound via hands of the surgical personnel or by instruments used [84, 85]. Several 
studies have been performed on the amounts of colony forming units (CFUs) at the surgical 
site, airflow in the operating room, discipline in the operating room and particle counts 
[82, 86-90] all with different results. Although these results are contradictionary, it has 
been suggested that levels of CFU should be maintained at < 10CFU/m3 during implant 
surgery, and that clinical benefits can be expected by reducing it to 1 CFU/m3 [91]. 
Chapter 6 focused on air quality and the effect of door-openings on the number of CFUs, 
measured during hip revision arthroplasty, classified as being a high risk operation. It was 
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hypothesized that a reduced frequency of door-openings will lead to reduced numbers 
of CFUs during surgery. 
The patient
Although several improvements such as the use of prophylactic antibiotics and laminar 
airflow in the operating room contributed to reduce infection rates after total joint 
arthroplasties, the risk of infection has not been eliminated. Contrary, infections 
rates in the modern hospital centers are higher than compared to that in the 1970s, 
since nowadays, more elderly people and patients with preexisting co-morbidities are 
undergoing a total joint arthroplasty [92]. The patient-related factors which might have 
an influence on the development of infection are very important, however are outside 
the scope of this thesis and therefore not discussed here. 
Imaging of bone remodeling
Radiographs are used to evaluate patients after hip revision surgery with BIG [14, 24, 30, 
31]. Radiolucent lines as well as position of the prosthesis are identified to detect possible 
loosening. However, radiographs do not provide information on the process of bone 
remodeling after BIG and the appearance of the graft is difficult to interpret radiologically 
[93]. To gain more insight in this process, biopsies or autopsies from the graft material have 
been evaluated histologically [94, 95]. Results showed that bone remodeling is slow and 
that bony healing after hip revision surgery with BIG may be less predictable compared 
to primary hip arthroplasty. Ullmark et al. [96] used positron emission tomography 
(PET) to study bone metabolism and bone formation in allografts surrounding the femur 
component in revision surgery. They concluded that bone metabolism was significantly 
reduced at 6 years after the surgery, when compared to the elevated activity during the 
first year postoperatively, but also when compared to the contra-lateral side.  
To understand bone remodeling around primary prosthetic hip implants, several studies 
used Dual-Energy X-ray Absorptiometry (DEXA) [97-105]. DEXA is a relatively cheap 
method with low radiation burden. However, less is known on DEXA and hip revision 
arthroplasty with bone impaction grafting. Laursen et al. [106] studied experimental 
defects around acetabular components in human post mortem pelvis specimens. They 
concluded that DEXA scanning provides a sensitive measure of changes in bone mineral 
content (BMC) around cementless hemispherical metal-backed cups. 
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Since early visualization of increased bone resorption might be of importance for early 
diagnosis of bone loss, DEXA might be a tool for quantification of changes in bone content 
and bone remodeling. Therefore, in chapter 7 of this thesis DEXA for bone impaction 
grafting and bone remodeling after hip revision surgery was evaluated.
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ABSTRACT
The aim of this review was to discuss the current state of research of combining 
bisphosphonates with allograft bone for implant fixation. The allograft bone can 
only be reached by the bisphosphonate once it has been revascularized. However, 
this can be circumvented by local administration of bisphosphonates. Several animal 
studies showed that local application of bisphosphonates might protect the graft 
from resorption. There seems to be an optimum concentration for local application, 
however, this optimum varies for all different bisphosphonates. It can be concluded 
that local administration of bisphosphonates might play an important role in 
improving stability after surgery in which a prosthesis is combined with allograft bone 
to restore bony defects, however caution should be taken when extrapolating results 
of animal research to the human clinical situation. More research is needed to study 
the effect of local bisphosphonate use in humans and to study possible side effects.
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Background 
Bisphosphonates are used for a variety of bone diseases in which excessive osteoclast 
activity is an important feature, including Paget’s disease, bone tumors and, of course, 
osteoporosis [1]. Their ability to reduce the risk of fractures has saved thousands of people 
from becoming fracture patients. More recently, suggestions have been made on the use 
of bisphosphonates in fracture repair and implant fixation [2]. As research on the use of 
bisphosphonates has mainly focused on osteoporosis, their effects on repair processes 
have long been disregarded. Osteoporosis is due to an imbalance in bone remodeling. 
This remodeling is different from the repair processes that occur after fracture or bone 
surgery [3]. In bone remodeling, osteoclasts and osteoblasts work closely together. Their 
activities are coupled, i.e. a decrease in bone resorption due to bisphosphonates leads 
to a reduction in bone formation to a similar degree. Therefore, it was thought that 
bisphosphonates would only slow down bone repair. However, in bone repair, osteoblasts 
can work independently. Osteoblasts are metabolically demanding cells with high levels 
of energy consumption, requiring an adequate blood supply, while there is no relation 
between osteoclasts and vascularization [4]. Therefore, a trend towards an increase in bone 
resorption can be expected when vascularization is absent, after surgery. A reduction in 
osteoclastic activity might therefore shift the balance between formation and resorption 
towards increased net bone formation [2].
Bisphosphonates bind to bone mineral and are taken up by osteoclasts when these cells 
resorb bone, which subsequently inactivates them. Bisphosphonates can be divided into 
two groups with different modes of action. The first group contains bisphosphonates, such 
as etidronate and clodronate, that closely resemble pyrophosphate. The bisphosphonate 
can be metabolically incorporated into nonhydrolyzable analogs of ATP that may 
inhibit ATP-dependent intracellular enzymes in the osteoclast, subsequently resulting 
in apoptosis of the osteoclast. The more potent, nitrogen-containing bisphosphonates, 
such as zoledronate, alendronate and ibandronate, inhibit the mevalonate pathway. The 
inhibition of protein prenylation results in the loss of osteoclast activity and induction 
of apoptosis. [5, 6].
The initial fixation of joint prostheses appears to be crucial for long-term success. The 
surfaces of joint replacements are mostly adjacent to cancellous bone. Due to the operative 
trauma or circulatory disturbance, osteocytes next to an implant will die. Bisphosphonates 
may inhibit resorption of the bone next to the prosthesis, which can be nothing but 
necrotic and prone to resorption. Another possibility is that the response to the trauma 
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gets a more positive balance between bone formation and resorption [1, 7]. An overview 
of literature on this subject has been written by Aspenberg [2]. It was concluded that, 
although antiresorptive, bisphosphonates may increase the amount of bone adjacent to 
an implant, leading to better implant fixation. This has already been shown in several 
clinical studies, however, should be further evaluated [8, 9]. 
Allograft bone is often used in reconstruction of (large) bone defects around failed 
implants. Bone impaction grafting with allograft bone is an example of the use of 
allograft bone in reconstructive surgery. It has been used in clinical practice since 1979 
for acetabular reconstructions and since 1987 for femoral reconstructions with satisfying 
clinical results [10, 11]. With the bone impaction grafting technique, bone defects in 
acetabulum and femur are restored with metal meshes. Thereafter, the defect is filled with 
tightly impacted morselized cancellous bone chips and a cemented prosthesis is placed. 
The allograft bone serves as a scaffold and the short-term success of revision arthroplasty 
with impaction grafting is related to the initial stability of the construct. The allograft 
bone is resorbed by osteoclasts and new bone, formed by osteoblasts, can grow into the 
allograft. The remodelling of newly formed bone into its characteristic structure will lead 
to the biological repair of the defect following surgery.
Bisphosphonates might also improve implant fixation when combined with allografts, 
as the same principle appears to apply to allograft bone, which is in fact necrotic bone 
next to the prosthesis. To improve mechanical stability and to prevent migration of the 
implant after surgery, bisphosphonates might be administrated either systemically or 
locally. The aim of this review was to discuss the current state of research of combining 
bisphosphonates with allograft bone for implant fixation. 
Systemic administration of bisphosphonates in combination with 
allografts 
Several studies have been performed on the systemic administration of bisphosphonates 
after primary arthroplasty [12-18]. It can be concluded from these studies that 
bisphosphonates reduce periprosthetic bone loss, increase the amount of peri-implant 
bone and decrease micromovements at the bone-implant interface after primary implant 
arthroplasty, however, long-term follow-up is not available. Systemic administration of 
bisphosphonates in combination with allograft bone has been less studied. The effect of 
systemic administration of zoledronate on the resorption of allograft bone was studied 
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using bone chambers in rats [19]. Higher amounts of both allograft bone as well as newly 
formed bone were found in the bisphosphonate group when compared to controls. It was 
concluded that zoledronate can be used to decrease bone resorption of graft bone as well 
as increase new bone formation during remodeling. 
Long-lasting use of bisphosphonates might be harmful. One of the problems associated 
with long-term use of bisphosphonates is the development of microcracks, which might 
be promoted through excessive mineralization [20]. Another problem associated with 
systemic bisphosphonate treatment is osteonecrosis of the jaw. It was suggested that the 
incidence of osteonecrosis of the jaw is higher in zoledronic acid treatment than when 
other bisphosphonates are used. [21]. No reports of osteonecrosis of the jaw or of the 
development of microcracks have been published after systemic administration of a 
bisphosphonate after primary arthroplasty, nor when it is used systemically in combination 
with allograft bone in animal studies. 
However, since the application of bisphosphonates in combination with allograft bone is 
relatively new, problems associated with the use of bisphosphonates known from other 
applications should be borne in mind.
Systemic administrated bisphosphonates only reach vascularized bone and the necrotic, 
allograft bone can only be reached by the bisphosphonate once it has been revascularised 
[22]. Furthermore, blocking necrotic bone resorption, as in the case of a bone graft, may 
require higher local concentrations, which may be difficult to achieve with systemic 
treatment [23]. Such problems would be solved if the graft could be treated before 
implantation.  
Local administration of bisphosphonates in combination with allografts: 
animal studies
Allograft pretreated with a bisphosphonate might protect the graft from being resorbed, 
without affecting the entire skeleton [24]. Higher local concentrations of the drug 
can be used when compared to the systemic administered concentration of the drug. 
Bisphosphonate solution has been administered locally in combination with allograft 
bone in animal studies. However, all studies used different species, bisphosphonates and 
techniques, and showed different findings. Table 2.1 gives an overview of studies using 
local application of bisphosphonates and their results.   
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Jakobsen et al. [25] used alendronate to impregnate the allograft before impaction in a 
dog model. Results were compared to allograft bone which was not impregnated with a 
bisphosphonate. Their results showed that the formation of new bone was inhibited in 
the alendronate groups, when compared to the control groups. Furthermore, alendronate 
decreased the biomechanical implant fixation and preserved the allograft. Jeppson et al. 
[26] studied allograft bone in bone conduction chambers in 42 rats. The allograft bone 
was impacted, impregnated with clodronate and rinsed three times with saline to wash 
away unbound bisphosphonate. Moreover, osteogenic protein 1 (OP-1) was added to 
the allograft-clodronate combination to stimulate bone formation. Two different bone 
densities of the bone grafts were used, unimpacted bone with a bone density of 38% and 
impacted bone with a bone density of 64%. After six weeks, bone density had greatly 
increased in both groups, however the ingrowth distance of new bone in the densely 
impacted group was reduced. They concluded that there might be a physical obstacle that 
prevents cells from entering the graft, if the graft is densely impacted. Also, Baas et al. 
[27] were not able to change the balance between bone formation and bone resorption. 
The bisphosphonate pamidronate virtually blocked bone metabolism in their study. 
Moreover, Belfrage et al. [28] studied zoledronate without rinsing the graft before use 
and concluded that it might have a negative effect on bone formation and bone ingrowth. 
On the contrary, it has been shown that local bisphosphonate treatment can protect the 
graft from resorption during the early postoperative period. Tagil et al. showed this in 2 
different studies [22, 29] with different bisphosphonates (zoledronate and alendronate, 
respectively). In both studies, bone graft in a bone conduction chamber in rats, not 
pre-treated with a bisphosphonate was resorbed after six weeks. In contrast, the bone 
chambers with graft bone which was pre-treated with a bisphosphonate were filled with 
dense trabecular bone consisting of both new bone and bone graft. 
These contradictory results led to hypothesis that large, locally applied amounts of 
bisphosphonate would have a negative effect on bone formation. Therefore, Agholme 
et al. [24] conducted a bone chamber study in rats, in which an excessive amount of 
alendronate was tested. The amount tested was 2 mg/mL, however, grafts were not rinsed 
after impregnation. Also, an allograft group with an amount (2 mg/mL, with rinsing of the 
graft after impregnation) of bisphosphonate of which the positive effect on bone formation 
had been shown earlier [30], and a control group were studied. No differences between the 
two bisphosphonate groups or negative effects on the bone grafts could be found. Their 
results showed protection of the graft and increased bone ingrowth in the alendronate 
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groups. Jacobsen et al [31] studied impacted morselized allograft bone impregnated with 
three different doses of zoledronate in dogs: 0.005 mg/mL, 0.05mg/mL and 0.5 mg/mL. 
They found a dose-dependent difference in the mechanical fixation of the implants, 
which was defined as the shear strength, shear stiffness and the energy absorption. Best 
mechanical implant fixation was found in the low dose and control groups. Also, no new 
bone formation was observed around the implants in the group with the highest dose 
of zoledronate. Formation of new bone on the surface of the implants in the high-dose 
group was blocked. A third study on dose effects of bisphosphonates was conducted by our 
research group [32]. 25 goats received 8 bone conduction chambers each with impacted 
allograft bone which was impregnated with different alendronate solutions: 0.5 mg/mL, 
1 mg/mL, 2 mg/mL, and 10 mg/mL. In accordance with the results of Jacobsen et al. [31], 
high doses of bisphosphonate had a negative effect on bone formation. 
It is difficult to compare these three studies, since different models, species and bisp-
hosphonates were used. Both Agholme et al. [24] as well as our research group [32] used 
alendronate to impregnate the allograft bone. The highest dose in the study of Agholme 
et al. was 2 mg/ml, without rinsing the allograft with saline after impregnation, with no 
negative effect on bone formation. This dose was also evaluated in a study by our group 
in which a decrease in bone formation was found after rinsing the allograft with saline 
after impregnation with alendronate in a goat model. However, highest impact on bone 
formation was found at a concentration of 10 mg/ml, which was much higher than the 
highest concentration used in the study of Agholme et al. Moreover, Agholme et al. used 
a rat model and did not impact the allograft bone. Jacobsen et al. [31] used zoledronate in 
combination with impacted allograft in a dog model, which makes it difficult to compare 
concentrations.
Most studies mentioned above were performed using bone chambers in different animal 
models. Caution should be taken when extrapolating the results to the human situation. 
The bone chamber model used is un-loaded and therefore quite different from the loaded 
conditions as in a clinical situation. Also, no cement has been applied, as is done in a 
cemented revision hip arthroplasty with bone impaction grafting, and other factors like 
vascularity, composition of the host bone bed and its interaction with the bone graft are 
not included in these studies. 
It can be concluded that local administration of bisphosphonates combined with 
allograft bone is effective in protection against resorption of the allograft bone in animal 
models. This might increase implant fixation after procedures in which allograft bone in 
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combination with a prosthesis has been used. The use of bisphosphonates might therefore 
be suitable if structural support is needed from the graft. In cases in which no structural 
support is needed the inhibition of resorption of allograft bone plays a less important role. 
There is an optimum concentration for local use of bisphosphonates in combination with 
allograft bone, however, this optimum varies for all different bisphosphonates. Studies, 
in which impacted allograft bone was used, show that impaction did not have an adverse 
effect on bone remodeling. However, if the allograft bone is too densely impacted, bone 
remodeling might be impaired. 
Local administration of bisphosphonates in combination with allografts: 
studies in humans
To the best of our knowledge, there is only one study in humans that combined local 
application of bisphosphonates with allograft bone (Table 2.1). Kesteris and Aspenberg 
[23] soaked allograft bone in an ibandronate solution and used the bone grafts during hip 
revision surgeries. Patients were followed up to 24 months and were compared to controls, 
which were treated with placebo solution. DEXA scans were taken to study bone density. 
They concluded that rinsing of morselized bone grafts with bisphosphonates prevents 
resorption and is likely to reduce the risk of mechanical failure. In control patients the 
grafts were already partially resorbed after three months, whereas the grafts treated with 
bisphosphonate increased in density postoperatively and then remained unchanged 
for two years. However, long-term follow-up is not available and the application of 
bisphosphonates in combination with allografts in humans has to be studied in more detail. 
Effects on osteoblasts
Although the primary action of bisphosphonates is to inhibit the osteoclasts, there is 
increasing evidence that bisphosphonates also interact with osteoblasts. Bisphosphonates 
might enhance proliferation and maturation of osteoblasts, and inhibit apoptosis, leading 
to increased bone formation [33]. These anabolic effects of bisphosphonates on bone 
formation are confirmed in several in vitro [34-38] and in vivo studies [7]. In animal 
studies on local administration of bisphosphonates combined with allograft bone, the 
amount of new bone increased significantly when compared to the control group, if the 
graft was pretreated with a bisphosphonate [30-32, 39, 40]. A possible explanation of the 
increase in newly formed bone, might be the rapid remodeling by osteoclasts. In grafts 
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not treated with a bisphosphonate, osteoblasts form new bone, however, osteoclasts 
immediately resorb the newly formed bone. In grafts treated with a bisphosphonate 
the newly formed bone is not resorbed. This yields a net higher amount of new bone, 
which is entirely the result of the inhibition of osteoclastic activity and might explain the 
differences observed. Another explanation for the increase in newly formed bone has 
been proposed by Jakobsen et al. [31] They stated that the increase in bone formation 
might be explained by the preserving effect of the bisphosphonate on the allograft, 
thereby prolonging the osteoconductive effect. A third explanation for the decrease in 
newly formed bone in the presence of high doses of bisphosphonates might be the lack 
of space. The necrotic, allograft bone is not resorbed and therefore, no room is left for 
the formation of new bone. 
At a high dose, bisphosphonates have been shown to be toxic to osteoblasts [37, 41]. 
Iwata et al. [42] concluded that bisphosphonates suppress osteoblastic activity at bone 
remodeling sites. It has been suggested that at a high dose bisphosphonates might 
have a cytotoxic effect on the osteoblasts [13, 38]. Naidu et al. [38] concluded that the 
effect of zoledronate on proliferation was dependent on its concentration, with a clear 
cut-off concentration. These cut-off and cytotoxic concentrations vary for each type of 
bisphosphonate. 
Conclusion
Systemic administrated bisphosphonates might protect allograft bone from too fast 
resorption, however, only vascularized bone can be reached. The allograft bone can only 
be reached by the bisphosphonate once it has been revascularized. However, this can be 
circumvented by local administration of bisphosphonates. Local administration protects 
the graft from resorption and might stimulate bone formation. There is an optimum 
concentration for local use, however, this optimum varies for all different bisphosphonates. 
If the local concentration of the bisphosphonate is too high, bone metabolism is blocked, 
which has a negative influence on bone ingrowth and mechanical stability. 
Local administration of bisphosphonates might play an important role in improving 
implant stability after surgery in which allograft bone is used to restore bony defects, 
however, however caution should be taken when extrapolation results of animal research 
to the human clinical situation. More research has to be done to study the effect of local 
use of bisphosphonates in humans.
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ABSTRACT
Background: Bone grafts from bone banks might be mixed with bisphosphonates 
to inhibit the osteoclastic response. This inhibition prevents the osteoclasts to resorb 
the allograft bone before new bone has been formed by the osteoblasts, which 
might prevent instability. Since bisphosphonates may not only inhibit osteoclasts, 
but also osteoblasts and thus bone formation, we studied different bisphosphonate 
concentrations combined with allograft bone. We investigated whether locally applied 
alendronate has an optimum dose with respect to bone resorption and formation. 
Further, we questioned whether the addition of demineralized bone matrix (DBM), 
would stimulate bone formation. Finally, we studied the effect of high levels of 
antibiotics on bone allograft healing, since mixing allograft bone with antibiotics 
might reduce the infection risk. 
Methods: 25 goats received eight bone conduction chambers in the cortical bone 
of the proximal medial tibia. Five concentrations of alendronate (0, 0.5 mg/mL, 
1 mg/mL, 2 mg/mL, and 10 mg/mL) were tested in combination with allograft 
bone and supplemented with cefazolin (200 µg/mL). Allograft not supplemented 
with alendronate and cefazolin served as control. In addition, allograft mixed with 
demineralized bone matrix, with and without alendronate, was tested. After 12 weeks, 
graft bone area and new bone area were determined with manual point counting. 
Results: Graft resorption decreased significantly (p<0.001) with increasing 
alendronate concentration. The area of new bone in the 1 mg/mL alendronate 
group was significantly (p=0.002) higher when compared to the 10 mg/mL group. 
No differences could be observed between the group without alendronate, but with 
demineralized bone, and the control groups.
Conclusions: A dose-response relationship for local application of alendronate has 
been shown in this study. Most new bone was present at 1 mg/mL alendronate. Local 
application of cefazolin had no effect on bone remodelling.
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Different types of bone grafts from bone banks are widely used for the restoration of 
bone defects in clinical practice with satisfying clinical outcomes [1, 2]. In addition, 
allograft bone bank chips are used during bone impaction grafting, a well-accepted and 
clinical successful procedure for the restoration of bone stock loss around loose implants 
[3-5]. This procedure is hence applied during revision arthroplasty. A possible problem 
associated with the use of bone grafts in loaded conditions, like in revisions, is a too fast 
resorption of graft material. Accelerated bone graft resorption before the formation of 
new bone may cause loss of stability, ultimately resulting in failure of the revised hip or 
knee implant [6-8]. 
Bisphosphonates might reduce bone graft resorption by inhibition of the osteoclasts [9]. 
Bisphosphonates have a high affinity for Ca2+, and therefore are targeted to areas of high 
bone turnover and adhere closely and selectively to sites of active bone remodelling. 
Osteoclasts trying to resorb the bone, release the bisphosphonates from the bone mineral. 
Bisphosphonates become internalized in the osteoclast, resulting in apoptosis of the 
osteoclast [10]. 
Although bisphosphonates efficiently suppress bone resorption by apotosis of osteoclasts, 
systemic treatment will only reach the revascularized parts of the bone graft and the 
concentration of bisphosphonates in regions of the skeleton with low blood perfusion, 
for example the femoral neck, will be very low [11-13]. Therefore, in several studies a 
bisphosphonate solution was administered locally, with varying results [9, 12, 14-17]. 
In these studies, it was hypothesized that local application of bisphosphonates would 
decrease resorption after implantation of a new prosthesis. This might prevent mechanical 
instability and therefore provide better support during the early process of healing after 
the operation. This way, bone resorption and bone formation might be more balanced. 
Baas et al. [16] were not able to change this balance between bone formation and bone 
resorption. The bisphosphonate virtually blocked bone metabolism in their study. In 
addition, Jakobsen et al. [15] found a substantially decreased biomechanical implant 
fixation when the impacted morselized allograft had been soaked in bisphosphonate. On 
the contrary, it has been shown that local bisphosphonate treatment can protect the graft 
from resorption during the early postoperative period [9, 12]. It has been suggested that 
bisphosphonates not only inhibit osteoclastic activity, but also might have a decreased 
anabolic or even a toxic effect on osteoblasts; a too high concentration of the unbound 
bisphosphonate may not only inhibit the osteoclasts but also the osteoblasts, and thus 
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reduce new bone formation [18]. It is therefore important that the concentration of 
unbound free bisphosphonate is below the level in which osteoblasts are inhibited [9, 
15, 16, 19, 20].
The chance of failure of a reconstruction is greatest immediately after surgery, when the 
graft bone has not been incorporated yet. This critical period after reconstruction with 
bone impaction grafting might be shortened when demineralized bone matrix (DBM) 
is used. DBM is a product of processed allograft bone and contains collagen, proteins 
and growth factors [21]. Demineralization of bone theoretically facilitates the release of 
growth factors which could increase the bioactivity of the graft and positively influence 
new bone formation and thus the amount of new bone [22, 23] which might be of 
importance during the early critical period.   
Another devastating complication following joint replacement surgery is infection. 
Systemic administered antibiotics are widely used to prevent and cure infection, however 
these antibiotics cannot easily reach the infected bone in an avascular area [24]. In 
addition, formation of a biofilm on the surface of the implant makes the systemic 
administered antibiotics less effective [25]. A solution to achieve high local antibiotic 
concentrations is to impregnate bone allograft chips with antibiotics. Several studies have 
shown that morselized bone can act as a carrier for antibiotics [26-32]. These studies 
show, both in vitro as in vivo, that bone grafts impregnated with antibiotics can be used 
as a prophylaxis against infections. However, the effectiveness of bone allograft healing 
in the presence of high levels of antibiotics has yet to be determined. 
In this study we combined the local application of bisphosphonate, DBM and antibiotics 
with allograft bone chips in a bone chamber. The purpose of this study was to investigate 
the dose-response relation of alendronate-impregnated allograft with respect to the 
amount of graft bone and the amount of new bone or total bone after 12 weeks. We 
investigated whether locally applied alendronate has an optimum dose with respect to 
bone resorption and net bone formation. The second question of this study was whether 
the addition of DBM to bone chips impregnated with bisphosphonate would stimulate 
bone formation. Finally, we investigated whether the local application of antibiotics has 
an effect on bone remodelling.
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meThodS 
Study design
25 mature Dutch female goats (Capra Hircus Sana, range 49-70 kg) bilaterally received 
four bone chambers in the cortical bone of the proximal medial tibia. The side and 
position of implantation of the 8 chambers were alternated with a random start. The bone 
conduction chamber consists of a titanium screw with a cylindrical interior space [33]. 
It is made up of two threaded half-cylinders held together by a hexagonal closed screw 
cap. The interior of the chamber has a diameter of 2 mm and a length of 7.5 mm. There 
are two openings at the end of the chamber to enable bone ingrowth. The threaded end 
of the implant is screwed into the tibia of the goat, so that the ingrowth openings are in 
direct contact with the endosteal transition from marrow into bone. Originally developed 
as a rat model, the bone conduction chamber was adjusted for use in goats [34]. Since 
the tibial cortex in rats is thinner than in goats, a 1-mm thick plate was inserted into the 
cap to lower the ingrowth openings through the cortex.
Five concentrations of bisphosphonates (0, 0.5, 1, 2, and 10 mg/mL alendronate, 
Fosamax, MSD) were combined with allograft bone supplemented with antibiotics (200 
µg/mL cefazolin) (ALL+AB, ALL+AB+0.5BIS, ALL+AB+1BIS, ALL+AB+2BIS, and 
ALL+AB+10BIS). Allograft not supplemented with alendronate and cefazolin served 
as control (ALL). In addition, allograft mixed with DBM with alendronate (1 mg/mL) 
(ALL+DBM+BIS) and without alendronate (ALL+DBM) were tested (Table 3.1). The 
observation time was 12 weeks.
Table 3.1 Overview of experimental design
Group Alendronate (mg/mL) Cefazolin (µg/mL) DBM
ALL - - -
ALL+AB - 200 -
ALL+AB+0.5BIS 0.5 200 -
ALL+AB+BIS 1 200 -
ALL+AB+2BIS 2 200 -
ALL+AB+10BIS 10 200 -
ALL+DBM - - +
ALL+DBM+BIS 1 - +
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Our sample size calculation was based on the results of a study of Aspenberg and Astrand 
[9]. The minimal relevant difference of bone formation was set to 27% and based on this 
study, we assumed the standard deviation on the relative change to be 8%. Two sided α 
and β were set to be 5% and 10% respectively. 
All procedures were approved by our institutional Animal Ethics Committee.
Bone graft preparation
Cancellous bone graft was obtained under sterile conditions from the sternum of three 
donor goats. Bone grafts were morselized into chips of approximately 1–2 mm, pooled 
and rinsed with saline with pulse lavage (Pulsavac® Plus, Zimmer, Swindon, UK) for two 
minutes to remove blood and marrow.
Bone chips were impregnated with 5 ml alendronate (Fosamax, MSD) and/or 5 ml 
cefazolin solutions for 10 minutes, then rinsed 3 times in 5 ml saline at room temperature 
for 3 minutes. Rinsing was done to remove unbound and excessive alendronate and/or 
cefazolin. Alendronate solution was prepared by dissolving one 10 mg tablet in 5 ml of 
saline for 1 hour and then passing it through a sterile Millipore filter with a pore size of 
0.2 mm. To obtain the different concentrations, this alendronate solution was diluted.  
The concentration of cefazolin was 200 µg/mL. This concentration was based on an 
earlier performed in vitro study, in which the amount of antibiotics on the allograft bone 
was determined after impregnation of the bone chips with cefazolin [35]. The amount 
of cefazolin present on the bone chips after rinsing 3 times with saline was determined 
and appeared to be well above the Minimal Inhibitory Concentration (MIC) for S. 
Epidermidis and about 1/3 of the amount of cefazolin present on the bone chips without 
rinsing. Additional data (unpublished) showed that impacting the bone graft chips after 
impregnation with cefazolin, did not have an effect on the amount of cefazolin present 
on the bone chips, compared to not impacting the bone chips. Tests were performed 
according to the protocol as described earlier [35]. According to Edin et al. [36], local 
levels of cefazolin of 200 µg/mL decrease cell replication, but local levels of 100μg/mL do 
not affect the replication of osteoblasts. Freeze-dried DBM (size 80–800 µm) was prepared 
at DIZG (Deutsches Institut fur Zell- und Gewebeersatz, Berlin, Germany) from the 
cortical bone of two donor goat femora under sterile conditions. DBM was rehydrated 
and mixed with the cancellous bone graft chips in a 50/50 volume ratio. 
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Impaction was performed by gradually filling the chambers with the allograft preparations. 
A piston slightly smaller in diameter (1.9 mm) was used for impaction. The piston 
was guided by low friction bearings, strictly limiting it to vertical movement. During 
impaction, the chamber was clamped into a cylindrical holder. A constant force of 40N 
was kept on the free end of the piston for two minutes. During this time, fluid could escape 
between the piston and the wall of the bone chamber and the ingrowth openings. The 
pressure applied was calculated to be 25 MPa. With this method of impaction, the mean 
volume fraction of graft bone in the bone chamber rises from about 35% in unimpacted 
grafts to about 65% in impacted ones [37]. After impaction, the screw cap was placed on 
the cylinder and the bone conduction chamber was stored at -80˚C until use. The bone 
chambers were thawed at room temperature before implantation. 
Surgical procedure
Goats were anesthetized with medetomidine (5 µg/kg) and propofol (3–5 mg/kg), 
intubated, and maintained using isoflurane and oxygen in a semiclosed ventilation system. 
The goats were placed in supine position. The lower legs were shaved, washed, iodized 
and covered with sterile cloths. A longitudinal incision was made in the skin and fascia 
over the medial side of the proximal tibia. The cortical bone was explored and a hole 
was drilled through the medial cortex at approximately 4 cm from the joint cleft using 
a 3.2-mm drill. The hole was tapped and bone debris from drilling was removed. The 
bone conduction chamber was screwed in manually. The other three bone conduction 
chambers were placed 10 mm from each other. This was repeated for the other side. The 
skin was sutured in two layers. 
After the operation, goats received injections of antibiotics (15 mg/kg) (ampicilline) and 
analgetics (1 mg/kg) (flunixin). All animals were allowed unrestricted movement in their 
cages and had free access to water and food after the operation. After 12 weeks, the goats 
were killed with an overdose of sodium pentobarbital (0.5 mL/kg).
histological and histomorphometric evaluation
Tibiae were removed and the bone conduction chambers with surrounding cortex were 
fixed in 4% buffered formalin. After 1 day the contents were removed from the bone 
chambers and fixed additionally for at least 5 days. After dehydration in ethanol and plastic 
embedding (polymethylmethacrylate), non-decalcified 7-mm thick serial sections were 
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made along the longitudinal axis of the specimen. Sections were stained with hematoxylin 
and eosin and Goldner-Masson for routine histological analysis. Histomorphometric 
quantitative analysis was done blindly using digitalized pictures of the sections. Three 
central sections in each specimen were studied, each 250 µm apart. Manual point counting 
was performed using custom-made stereological software. The total number of points, 
points covering bone in general and points covering new living bone were counted. Graft 
bone was identified by its highly organized lamellas and oval cell lacunae without nucleic 
material, whereas newly formed bone was less organized and contained nucleic material. 
On average, 100 point were counted in each section, resulting in 300 points per specimen 
All sections were blinded and evaluated in random order. 
Statistics
Results were analysed non-parametrically, therefore Friedman’s repeated measurements 
ANOVA on ranks with a Wilcoxon signed ranks test with a Bonferroni adjustment was 
used to differentiate between groups.  
SPSS software version 18.0 was used. Statistical significance was set at p<0.05.
ReSuLTS
All goats were able to stand normally on their hind legs 1 to 2 days after surgery. There 
were no signs of inflammation, skin ulceration or wound healing problems. Three goats 
died during the 12 week period, of reasons not related to surgery. These goats were not 
excluded from analysis, since they died a few days before sacrification. 8 bone chambers 
were loose and excluded, they originated from the control group (1), control with cefazolin 
group (2), 0.5 mg/mL alendronate group (1), 2 mg/mL alendronate group (1), 10mg/mL 
alendronate group (2) and of the DBM group (1).
histology
In general, bone chambers were surrounded by a layer of callus and covered with fibrous 
tissue. The graft bone in the control group was almost entirely resorbed (Figure 3.1A), 
while in the alendronate groups the bone chambers were full with graft bone as well as new 
bone (Figure 3.1B). A homogeneous distribution of DBM was present in non-resorbed 
areas within the bone chamber (Figure 3.1C). Two different incorporation patterns were 
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Figure 3.1 Histological results. A. Typical example of ALL+DBM group. Notice large area 
of fibrous tissue (FT) between graft remnants (right) and new bone (NB). B. Typical example 
of BIS+DBM group. Bone chamber is fully filled with a mixture of graft remnants, DBM and 
new bone. C. Non incorporated mixture of bone graft (BG) and demineralized bone (DBM) 
of ALL+DBM+BIS group. d. The incorporation front in a chamber with ALL. Arrows point at 
osteoclasts. e. Fibrous tissue surrounding bone grafts. ALL+AB+2BIS group. F. Osteoclasts 
on DBM bone particle. ALL+DBM group. g. Enlargement of bone in ALL+AB+2BIS group. 
Notice mixture of new bone (NB) with osteocytes and bone graft (BG). h. New bone formed 
in ALL+DBM group. J. Ossification (arrows) of BIS particles in bone chamber of ALL+DBM+BIS 
group. Bars are 1 mm (A, B), 500 µ (H), 250 µ (C, D, E, J) or 100 µM (F, G).  
C
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found in the ALL, ALL+AB, ALL+DBM groups on the one hand (Figure 3.1A) and all 
the other groups where BIS was added on the other hand. (Figure 3.1B). 
In all groups without BIS (ALL, ALL+AB, ALL+DBM) similar patterns of resorption 
and new bone formation were present. All bone graft (including DBM if present) was 
resorbed or a resorption front could be found at the interface with allograft remnants 
(Figure 3.1D). This front, if still present, consisted of numerous lymphocytic cells that 
had penetrated into the graft (Figure 3.1D). Numerous osteoclasts in a blood vessel rich 
area resorbed all allograft and DBM if present (Figure 3.1D). No obvious differences 
were found between the activity of osteoclasts on allograft bone or DBM (Figure 3.1D, 
3.1F). Between the resorption front and the area with new bone in almost all chambers a 
thick fibrous interface was present containing fibroblasts and some macrophages (Figure 
3.1A). New bone formation was mainly found at the direct vicinity of the ingrowth holes 
(Figure 3.1A, 3.1H). The newly formed bone contained no or scarce remnants of ALL or 
DBM. In most chambers a strong remodeling activity was still present as is visualized by 
the red non-calcified zones in the Goldner stained sections (Figure 3.1J).
In all groups with BIS the delineation of the resorption front was less clear. Lower 
numbers of osteoclasts were present on the bone graft particles (Figure 3.1E) compared 
to all groups without BIS. Histologically no clear differences could be found in the 
number of osteoclasts in the different BIS concentration groups. After the passage of the 
revascularization front through the bone graft, the non-resorbed ALL and/or DBM were 
surrounded by fibrous tissue (Figure 3.1E). Newly formed bone was present in a much 
larger area compared to all groups without BIS (Figure 3.1B). Bone was formed on the 
remnants of ALL or DBM (Figure 3.1G, 3.1J). No clear differences were found between 
the resorption of ALL and DBM. In the area with new bone most allograft bone was 
mineralized. In the Goldner stained sections some focal areas with non-mineralized DBM 
were present, but round green spots in the DBM particles suggest that they underwent a 
process of mineralization after incorporation into new bone (Figure 3.1J). 
histomorphometry
Cefazolin
No significant differences could be observed between the cefazolin group (ALL+AB) and 
the control group (ALL), for total bone volume, graft bone volume or new bone volume 
(Table 3.2, Figure 3.2 and Figure 3.3).
51
Im
pregnation of bone chips, a bone cham
ber study
Chapter 3
Alendronate
An alendronate dose-dependent difference in the amount of graft bone was found (Table 
3.2A, Figure 3.2). Graft resorption decreased with increasing alendronate concentration. 
All groups treated with alendronate differed significantly (p<0.001) when compared to 
the volume fraction of allograft bone of the control group. These significant differences 
for volume fraction of allograft bone were also observed between the four alendronate-
groups; with increasing amounts of alendronate, a decrease in graft resorption was found, 
which were all significantly different.  
Table 3.2A Overview of statistical results (graft bone)
Group ALL ALL+AB ALL+AB
+0.5BIS
ALL+AB
+BIS
ALL+AB
+2BIS
ALL+AB
+10BIS
ALL
+DBM
ALL+DBM
+BIS
ALL - - - - - - - -
ALL+AB 0.674 - - - - - - -
ALL+AB+0.5BIS <0.001* <0.001* - - - - - -
ALL+AB+BIS <0.001* <0.001* <0.001* - - - - -
ALL+AB+2BIS <0.001* <0.001* <0.001* 0.001* - - - -
ALL+AB+10BIS <0.001* <0.001* <0.001* <0.001* 0.003 - - -
ALL+DBM 0.003 0.003 <0.001* <0.001* <0.001* <0.001* - -
ALL+DBM+BIS 0.008 <0.001* 0.000* 0.001* 0.003 0.361 <0.001* -
* Significant: p<0.0018 (Bonferroni adjustment due to 28 different comparisons).
Table 3.2B Overview of statistical results (new bone)
Group ALL ALL+AB ALL+AB
+0.5BIS
ALL+AB
+BIS
ALL+AB
+2BIS
ALL+AB
+10BIS
ALL
+DBM
ALL+DBM
+BIS
ALL - - - - - - - -
ALL+AB 0.068 - - - - - - -
ALL+AB+0.5BIS <0.001* 0.059 - - - - - -
ALL+AB+BIS <0.001* <0.001* <0.001* - - - - -
ALL+AB+2BIS <0.001* <0.001* 0.007 0.219 - - - -
ALL+AB+10BIS <0.001* 0.285 0.049 0.002 0.018 - - -
ALL+DBM 0.344 0.181 0.001* <0.001* <0.001* <0.001* - -
ALL+DBM+BIS <0.001* 0.11 0.375 <0.001* 0.043 0.331 <0.001* -
* Significant: p<0.0018 (Bonferroni adjustment due to 28 different comparisons).
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Bone formation in the four alendronate groups was significantly different when compared 
to the control group (p<0.001) (Table 3.2B, Figure 3.3). 
When bone formation in the 1 mg/ml (ALL+AB+BIS) was compared to bone formation 
in the 10 mg/ml (ALL+AB+10BIS) group, the volume fraction of new bone was signifi-
cantly lower in the highest alendronate group (Table 3.2).  
Figure 3.2 Percentage graft bone of total volume for the 8 different groups.  
Figure 3.3 Percentage new bone of total volume for the 8 different groups.  
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Demineralized bone matrix
When the group with DMB (ALL+DBM) was compared to the control group, no 
differences could be observed (Table 3.2AB).     
dISCuSSIon
The purpose of this study was to investigate the dose-response relationship of alendronate-
impregnated allograft with respect to the amount of graft bone and the amount of new 
bone or total bone after 12 weeks in a goat bone chamber model. Also, the effects of 
adding DBM and the local application of antibiotics (cefazolin) were tested. 
We showed a dose-response relation for local application of alendronate with respect 
to the amount of new bone as well as the amount of graft bone present in the bone 
chamber after 12 weeks. Decreased implant fixation has been observed with higher 
doses of bisphophonates (by blocking bone metabolism completely) [16]. Therefore, an 
optimum dose regarding bone resorption is essential, since it yields a positive balance 
between allograft resorption and the net amount of newly formed bone which results 
in improved fixation.
Our results show that with increasing alendronate concentration, graft resorption 
decreased and the amount of necrotic graft bone, left after 12 weeks, increases. This is 
in accordance with the study of Jakobsen et al. [20], in which another bisphosphonate, 
zoledronate, was used. They also studied different bisphosphonate concentrations, 
however their volume fractions of allograft bone were much higher compared to our study. 
Our volume fractions of allograft bone were 10.9% (± 8.8) for the lowest alendronate 
group to 32.8% (± 8.7) for the highest alendronate group, while in the study of Jakobsen, 
graft bone volume fractions started with mean values above 30%. These differences in 
results might also be explained by the rinsing method used (3 min vs 10 min) or the fact 
that Jakobsen had a mechanically loaded situation compared to our unloaded situation. 
Agholme et al. [17] also used alendronate locally (2 mg/mL) and found volume fractions 
of allograft bone compared to ours. In contrast to our study, they did not find any 
differences between the amount of new bone between a regular dose (with rinsing after 
impregnation) of bisphosphonate and an overdose amount (without rinsing the graft after 
impregnation). The volume fractions of new bone were comparable to the mean volume 
fractions of the 4 different doses in our study, although we did find differences between 
the doses. They stated that their results may be explained by the four-week study period 
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in their experiments compared to the 6 weeks period in other studies (and thus the 12 
week period in our study), that there was not enough time to fully resorb all allograft 
bone behind the bone ingrowth frontier.  
Zoledronate is used in several studies for local application of bisphosphonate and is a 
more potent bisphosphonate compared to alendronate [38]. Differences in graft volume 
fractions between local application of alendronate and zoledronate might be explained 
by this. Alendronate was chosen in this study as bisphosphonate since it has been used 
as osteoporosis prophylaxis treatment for almost two decades [39]. 
The amount of new bone in our experiment showed an optimum at a dose of 1 mg/mL 
alendronate. The amount of new bone was significantly higher compared to control and 
also when compared to lower and higher alendronate concentrations. 
A possible explanation for the difference in newly formed bone between control and 
BIS groups is that in the control groups the newly formed bone is rapidly remodeled 
by osteoclasts. This yields a net low amount of new bone, which is entirely the result of 
osteoclastic activity and might explain the differences observed. Jakobsen et al. stated 
that this effect could be explained by the preserving effect of the bisphosphonate on the 
allograft, thereby prolonging the osteoconductive effect [20].
An enhancing effect of application of bisphosphonate locally on the amount of new bone 
has also been observed in other studies [9, 20, 40, 41] and are confirmed by some in vitro 
studies [19, 42-44]. However, it has not been shown in vivo. The declination in the amount 
of newly formed bone at the highest alendronate-group, compared to lower alendronate 
groups, might be explained by the toxicity of bisphosphonates on bone tissue. At a high 
dose, bisphosphonates have been shown to be toxic to osteoblasts [44, 45]. Another 
explanation might be the lack of space in the bone conduction chamber. The necrotic 
bone is not resorbed and therefore, no room is left for the formation of new bone. 
We chose cefazolin as antibiotic. This is the antibiotic of first choice for orthopaedic 
surgery in The Netherlands. According to Edin et al. [36] local levels of cefazolin 200μg/mL 
decrease cell replication, but levels of 100μg/mL do not affect the replication of osteoblasts. 
The amount of cefazolin used in this study is well above the MIC for S. Epidermidis, and 
did not affect bone remodelling since no differences between the control group and the 
allograft group impregnated with cefazolin could be observed between for % graft bone 
volume or % new bone volume. However, since our study was powered to show differences, 
not equality, this result should be interpreted cautiously. Taking into account the half-life 
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of cefazolin, it will stay above MIC – and be effective – for at least 8 to 10 hours which is 
enough for prophylaxis. Cefazolin is completely eluted from the bone chips after three 
days. No subinhibitory amount of the drug is left behind which can induce resistancies 
and therefore, cefazolin is an attractive choice for local prophylaxis [29].
No effect of the addition of DMB to allograft bone has been found in this study. In addition, 
histology shows similar resorption characteristics for DBM and allograft groups. The 
release of growth factors by osteoclastic resorption of allograft bone or DBM is probably 
quite similar. In addition, when combining DBM, alendronate and allograft bone, no 
additional bone was formed. Our results confirm several studies [46, 47], although 
other studies did find an enhancing effect of DBM on bone formation [48, 49]. Bae et 
al. [50] studied different DBM products and found a higher variability in concentration 
of bone morphogenic proteins among three different lots of the same DBM than among 
the different DBM products of different companies. Although our study pooled DBM 
of two goats (and therefore pooled two different lots), we did not find any effect of the 
addition of DBM to allograft bone. 
Before implantation of the bone chamber we impacted the allograft bone to simulate 
the clinical situation as much as possible. However, caution should be taken when 
extrapolating the results. This bone chamber model in goats is un-loaded and therefore 
quite different from the loaded conditions as in a clinical situation. Also, no cement has 
been applied, as is done in a cemented revision hip arthroplasty with bone impaction 
grafting. In addition, a limitation of this study is the lack of biomechanical testing that 
would determine whether the groups treated with alendronate would be structurally 
stronger than the control group. 
Basic principle of bone impaction grafting is that osteoclasts will resorb bone and 
osteoblasts will form new woven bone. Micromotions during normal gait cycles induce 
a rapid osteoclastic response. This too fast bone resorption might lead to intial instability 
of the implant, periprosthetic osteolysis and later implant migration [6, 7, 11, 51]. Local 
application of bisphosphonates has a clear influence on the osteoclastic activity, but 
little is known of the effect on implant migration and the occurrence of micromotions 
surrounding the implant. 
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Conclusions
In conclusion, a dose-response relationship for local application of alendronate with 
respect to graft resorption has been shown in this study. The area of new bone in our 
experiment was optimal at 1 mg/mL alendronate. At this concentration, the amount of 
new bone was significantly higher compared to control and also when compared to lower 
(0.5 mg/mL) and higher alendronate concentrations (2 mg/mL). Local application of 
cefazolin (200 µg/mL) had neither effect on bone formation nor on bone graft resorption. 
Therefore, cefazolin at this concentration might be used as a prophylaxis against infection. 
The addition of DBM did not enlarge the new bone area.
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ABSTRACT
Introduction: With bone impaction grafting, cancellous bone chips made from 
allograft femoral heads are impacted in a bone defect, which introduces an additional 
source of infection. The potential benefit of the use of preprocessed bone chips 
was investigated by comparing the bacterial contamination of bone chips prepared 
intraoperatively with the bacterial contamination of pre-processed bone chips at 
different stages in the surgical procedure. 
Methods: To investigate baseline contamination of the bone grafts, specimens 
were collected during 88 procedures before actual use or preparation of the bone 
chips: in 44 procedures intraoperatively prepared chips were used (Group A) and 
in the other 44 procedures pre-processed bone chips were used (group B). In 64 of 
these procedures (32 using locally prepared bone chips and 32 using pre-processed 
bone chips) specimens were also collected later in the procedure to investigate 
contamination after use and preparation of the bone chips. 
Results: In total, 8 procedures had one or more positive specimen(s) (12.5%). 
Contamination rates were not significantly different between bone chips prepared 
at the operating theatre and pre-processed bone chips.
Conclusion: In conclusion, there was no difference in bacterial contamination 
between bone chips prepared from whole femoral heads in the operating room and 
pre-processed bone chips, and therefore, both types of bone allografts are comparable 
with respect to risk of infection.
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InTRoduCTIon 
Total hip arthroplasty (THA) is one of the most successful medical procedures performed 
in an elderly population suffering from crippling osteoarthritis [1]. The number of THAs 
is expected to increase due to the ageing population, but also because hip prostheses are 
placed in patients who were formerly seen as too sick. Unfortunately, approximately 12% 
of these implants will fail in time and these patients will need hip revision surgery [1]. 
During hip revision surgery, bone impaction grafting (BIG) is a frequently used technique 
for reconstruction of bone defects [2-4]. With BIG, cancellous bone chips made from 
allograft femoral heads are impacted in the defect. However, the use of BIG introduces 
a potential source of infection. Prosthesis infection may occur post-operatively, but is 
often caused by bacterial contamination intra-operatively. Relatively small numbers of 
bacteria of low virulence are able to establish infection in the presence of the surgical 
implant and an abnormal functioning immune system [5-8]. 
The processing of femoral heads to obtain bone chips can be done in the laboratory of 
a bone bank or in the operating theatre during surgery just prior to use. As compared 
to bone chips prepared in the laboratory, we hypothesised that bone chips prepared 
intraoperatively may pose an additional risk for infection; the preparation of bone chips in 
the operation room takes about ten minutes, it necessitates the use of special instruments 
in the presence of all surgical team members, and due to the limited area in a down flow 
plenum system the preparation of bone chips often takes place outside the plenum. In 
contrast, preprocessed bone chips are prepared in a top-class level clean room with optimal 
controlled environmental conditions and no surgery time is needed for preparation. Also, 
during the process, specimens are collected to control for contamination and bone chips 
with positive bacterial cultures are discarded. 
The potential benefit of the use of preprocessed bone chips was investigated by comparing 
the bacterial contamination of bone chips prepared intraoperatively with the bacterial 
contamination of pre-processed bone chips at different stages in the surgical procedure.
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meThodS 
Patients
Consecutive patients on the waiting list for hip revision surgery were included. All 
surgeries were performed at Reinier de Graaf Groep, Delft and at Radboud University 
Medical Centre Nijmegen, both in The Netherlands. The study was approved by the 
Medical Ethics Committee. Written informed consent was obtained from all patients. 
To investigate baseline contamination of the bone grafts, specimens were collected 
during 88 procedures before actual use or preparation of the bone chips: in 44 procedures 
intraoperatively prepared chips were used (Group A) and in the other 44 procedures pre-
processed bone chips were used (group B). Patients were randomly assigned to group A 
or B. In 64 of these procedures (32 using locally prepared bone chips and 32 using pre-
processed bone chips) specimens were also collected later in the procedure to investigate 
contamination after preparation and impaction of the bone chips. 
Sample size calculation was based on the results of several studies on contamination 
of allograft femoral heads just prior to implantation [9-14]. Based on these studies, the 
minimal relevant difference was set to 7% and we assumed the standard deviation on 
the relative change to be 10%. Two sided α and β were set to be 5% and 10% respectively. 
Bone grafts
Allograft femoral heads were obtained from the bonebank of Sanquin, Nijmegen, or from 
Bislife, Leiden, both in The Netherlands. At the operating theater, the femoral head was 
thawed with warm saline for 15 minutes and then morselized with a bone mill (Novio 
Magus bone mill, Spierings Medical Technology, Nijmegen, The Netherlands).
Pre-processed bone chips were obtained from the bonebank of Sanquin, Nijmegen, 
The Netherlands. For the preparation of pre-processed bone chips, femoral heads were 
morselized under clean room conditions with a bone mill (Novio Magus bone mill, 
Spierings Medical Technology, Nijmegen, The Netherlands). Bone chips were then 
rinsed with sterile normal saline five times and placed in a sterile container and frozen at 
-80˚C. Sterility tests were performed throughout the process; bone chips with a positive 
culture were discarded. At the operating theater, chips were thawed with warm saline 
for 10 minutes. 
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Specimen collection
Specimens for bacterial culture were collected during the surgical procedure at four prede-
fined time points: 1) after unpacking the bone 2) after thawing the bone 3) after morselizing 
the bone in the operating theatre, and in case of pre-processed bone chips after opening 
the container of the chips to take out bone chips 4) after finishing the impaction grafting 
procedure from the already impacted bone chips, just before cementation. The additional 
specimens for investigation of the baseline contamination were collected at time point 1 and 2. 
Specimens were collected by one of the investigators (NM) in a standardized way using 
sterile single packed cotton wool tipped swabs (Peha Wattestäbchen, Paul Hartmann 
AG, Heidenheim, Germany). The bone surface was wiped down using 2 swabs held 
together until most of the bone area was swabbed, which was determined visually. At 
each predefined moment, a negative control was collected by holding 2 swabs together 
above the bone surface without collection of material. 
In the operation room, immediately after collection, the specimens and negative swab 
controls were placed in 10 mL of a thioglycolate broth (Oxoid supplemented with vitamin 
K1, hemin and E4 solution, Reinier de Graaf Hospital, Delft, The Netherlands). 
Culture 
After all materials for culture were collected, these were transported to the laboratory. 
Upon arrival the inoculated liquid broth media were directly incubated. Incubation was 
in 37°C for 5 days with subcultures performed after 2 days of incubation and at the end of 
incubation. Subcultures were performed using 2 sheep blood agars (Becton Dickinson), 
which were incubated for 48 hours at 37°C in 5% CO2 and under anaerobic conditions. 
Growth on the solid media was identified by matrix-assisted laser desorption ionization–
time of flight mass spectrometry (MALDI-TOF MS) using the Bruker Microflex LT with 
Biotyper version 3.0 (Bruker Daltonik GmbH, Leipzig, Germany).
Air quality control of operation room 
To control for differences in air quality as a potential cause of differences in contamination 
rates of the bone grafts detected, the environmental circumstances in the operating room 
were monitored during each surgery by measuring the amount of particles and colony 
forming units (CFUs) in the air. 
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Measurements of the amount of particles in the air were done with an Airborne Particle 
Counter (APC Plus, Kregliner Europe, Antwerp, Belgium), every 10 minutes for 1 minute 
during the surgery at a distance of approximately 1.5 m of the wound. 
The microbiological quality of the air was measured 4 times during surgery: directly after 
incision, directly after opening of the container of the femoral head or the opening of the 
container of the pre-processed bone chips, at the time the bone graft was first used in the 
procedure, and again 10 minutes later. At a distance of approximately 1.5 m of the wound, 
200 l of air with an airflow rate of 100 l/min was aspirated with a High Flow microbial 
Airborne Sampler (RCS High Flow, Kregliner Europe, Antwerp, Belgium) containing 
an RCS-strip with Tryptic Soy Agar (TSA, Kregliner Europe, Antwerp, Belgium). A 
sedimentation plate (TSA, Kregliner Europe, Antwerp, Belgium) was positioned on the 
instrument table where the bone chips were prepared at the moment of opening the 
container of the allograft bone for one hour. The number of CFUs on the sedimentation 
plate as well as on the RCS-strips was counted after 48 h of incubation at 30˚C and CFUs/
m3 was calculated.
Follow-up
The medical files were reviewed, including clinical, radiological, and laboratory findings, 
to assess the occurrence of an infection post-operatively.
Statistics
Chi Square test was performed to compare contamination of the intraoperatively prepared 
and the pre-processed bone chips, as well as the contamination of the negative control 
swabs. Air quality during the surgical procedures was investigated using the Mann 
Whitney U test. All statistical analyses were performed using PASW statistics 18.0. 
Differences were considered to be significant at p<0.05.
ReSuLTS
In 88 procedures, baseline contamination of the allograft bone was determined by 
collecting specimens at time points 1 and 2. Positive specimens were present in 5 
procedures (5.7%). In 64 procedures, specimens were also collected at later time points. 
In total, 8 procedures had one or more positive specimen (12.5%). Four procedures had 
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positive culture results at more than one time point. In one of these, a second bacterial 
species was cultured. Culture results are summarized in Table 4.1.
Contamination rates were not significantly different between bone chips prepared at the 
operating theatre and pre-processed bone chips. In 4 out of the 8 procedures with one or 
more positive specimen, femoral heads were used and in 4 procedures pre-processed bone 
chips were used. Also, when the total amount of contaminated specimens are compared, 
no significant differences could be found; 2.6% contamination of the chips prepared at 
the operating theatre and 5.3% contamination of the pre-processed bone chips (p=0.236). 
In total 3.9% of all bone cultures was positive. 
Of the negative control cultures 6.5% was positive. No significant differences could be 
found between the bone cultures and the negative control cultures (p=0.674). 12 control 
cultures from 11 procedures were positive. In 5 procedures, identical bacteria were 
recovered in the negative control swabs and in one or more of the bone specimens (Table 
4.1). In 5 procedures a single negative swab was culture positive with CoNS (S. hominis 
(n=2), S. warneri (n=2), S. epidermidis (n=1), S. pasteurii (n=1), Staphyloccus spp.) and 
in one procedure with Micrococcus spp. 
Air quality, defined by the amount of particles in the air, the microbiological quality of the 
air in the operating room (CFU/m3) and by the sedimentation plates on the instrument 
Table 4.1 Positive bone culture results
Procedure Bone culture (positive 
culture/total amount 
of cultures)
Microorganism Negative control
(positive culture/total 
amount of cultures)
Microorganism
1 2/4 PA 1/4 PA
2 1/4 CoNS 1/4 CoNS
3 1/4 MS - -
4 2/4 SW 1/4 SW
5 2/4 KS/CS - -
6 1/4 CS - -
7 3/4 RE 1/4 RE
8 1/4 SE 1/4 SE
Eight procedures with positive bone cultures. PA=propionibacterium acnes, CoNS=coagulase negative 
Staphylococcus, MS=Moraxella spp., SW=Staphylococcus Warneri, KS=Kocuria spp., CS=Corynebacterium 
spp., RE=Rhodococcus Erythropolis, SE=Staphylococcus Epidermidis.
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tables (CFU/m2), was not significantly different during the procedures in group A and 
group B. Results are presented in Table 4.2. 
Mean follow-up of the 8 patients with one or more positive bone cultures was 23 months 
(±7). Two of these patients developed an infection, however, in none of these patients the 
infection was caused by the bacteria isolated from the cultures at implantation.     
dISCuSSIon
It was hypothesized that during hip revision surgery with bone impaction grafting, culture 
specimens of femoral heads would be more contaminated compared to culture specimens 
of pre-processed bone chips, since these chips are prepared under more controlled 
environmental conditions. However, our results revealed no significant differences; culture 
positivity of specimens collected during hip revision surgery was similar in chips prepared 
at the operating room and in pre-processed bone chips. Air quality was measured during 
each procedure using a standardized protocol and could not account for these findings. 
The measured bacterial and particle counts during procedures using either bone chips 
prepared in the operating room or using pre-processed bone chips were comparable. In 
addition there was no quantitative correlation between air quality and positive cultures. 
The overall culture positive rate of the bone allografts was 3.9% and is within the range of 
3.4% to12% that has been reported previously [9, 15-17]. This range of reported culture 
positivity may be caused by differences in specimen collection methods and culture 
Table 4.2 Air quality results of hip revision surgeries
Group A Group B p-value
CFU/m3 84 ± 93 64 ± 64 0.302
CFU/hour/m2 2521 ± 4452 1991 ± 4004  0.640
Particles 0.3 µm 6995 ± 8214 3835 ± 3923  0.474
Particles 0.5 µm 655 ± 893 406 ± 493 0.440
Particles 1.0 µm 82 ± 92 52 ± 44 0.262
Particles 5.0 µm 4.4 ± 2.6 4.2 ± 2.8 0.546
Air quality results (±SD) of hip revision surgeries in which femoral heads were used versus hip revision 
surgeries in which preprocessed bone chips were used. Group A=femoral heads used during procedure, 
Group B=pre-processed bone chips used during procedure.
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methods. Sommerville et al. [15] showed increased culture positive rates with increased 
numbers of specimens and showed that surface swabs had low sensitivity as compared to 
bone and tissue biopsy. However, their method of swabbing was not described. Contrary, 
others argue that local tissue biopsies lack sensitivity and that swabbing the complete 
surface of the bone will detect most contamination since contamination of the living donor 
allograft is superficial and not evenly distributed on the graft [18]. Our study further 
shows that positive culture findings are not consistent when consecutive specimens are 
collected, despite swabbing of the whole surface. These inconsistent findings may reflect 
the very low numbers of contaminating bacteria that are present at baseline or later during 
the processing and use. At time point one, before thawing the bone, all cultures were 
negative, which may indicate that specimen collection from frozen bone is inadequate. 
The higher number of positive specimens collected at later time points could also reflect 
contamination of the allograft during manipulations in the operating room where there 
are always low numbers of bacteria present in the air as well as in the wound area [10, 19]. 
Most of the bacterial species that were recovered were typical skin bacteria including 
Staphylococcus spp., Corynebacterium spp., and P. acnes, while R. erythropolis, Kocuria 
spp., Micrococcus spp., and Moraxella spp. have been described as environmental bacteria. 
Most of these bacteria have been described as contaminants of bone allografts as well as 
contaminants of the surgical wound area and these results are in accordance with other 
studies. At the same time, intraoperative contamination of the prosthesis is considered to 
be the main cause of late prosthesis infections, and most of these bacterial species have 
been implicated in orthopedic prosthesis infection. 
Not much research has been done on contamination of bone allograft at implantation [9]. 
The clinical significance of these positive culture findings has been discussed earlier. In 
most patients positive culture findings of bone grafts were not related to late infections. 
In the current study, two of the eight patients with positive bone graft cultures, developed 
infection after a minimum follow-up of 23 months. However, in none of these patients 
the infection was caused by the bacteria isolated from the cultures at implantation. 
Since liquid broth culture media are susceptible to contamination of the culture system, 
positive cultures may not reflect true contamination of the bone allografts but may 
represent contamination that may occur during specimen collection, inoculation, or 
handling in the laboratory. Indeed, 12 of the 304 negative control swabs were culture 
positive. However, in 13 positive cultures including 4 negative control swabs, laboratory 
contamination was excluded because cultures became positive without handling in the 
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laboratory and thus must represent bacteria collected in the operating room either from 
the allograft bone material or from the direct environment. 
Pre-processed bone chips have the advantage of being more rapidly ready for use 
during surgery. The time advantage is estimated to be 10 to 15 min, although it could 
not be quantified in this study since most often, pre-processed chips were used in 
combination with whole femoral heads. In addition, since pre-processed bone chips are 
more thoroughly cleaned by rinsing the chips 5 times with saline and thereby washing 
cells and tissues out of the graft and reducing the immunological reaction, there may 
be a better incorporation of the allograft bone after bone impaction grafting [20]. On 
the other hand, a disadvantage of pre-processed bone chips may be the higher costs 
compared to unprocessed femoral heads. However, when considering the costs of a bone 
mill including the costs for sterilization and the time investment of the surgical team 
when preparing bone chips from femoral heads, bone chips prepared at the bone bank 
may actually be less expensive.
In conclusion, there was no difference in bacterial contamination of the allografts at 
baseline or during the surgical procedure between bone chips prepared from whole 
femoral heads in the operating room and pre-processed bone chips, and therefore, both 
types of bone allografts are comparable with respect to risk of infection. In the choice 
between pre-processed bone chips and preparation of bone chips in the operating room, 
other factors, such as time advantage, ease of use, and costs, must be considered.
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ABSTRACT
Background: Allograft bone used in joint replacement surgery can additionally serve 
as a carrier for antibiotics and serve as a prophylaxis against infections. However, 
in vitro dose-response curves for bone chips impregnated with different kinds of 
antibiotics are not available. In addition, while it would be desirable to add the 
antibiotics to allograft bone chips before these are stored in a bone bank, the effects 
of different storage temperatures on antibiotics are unknown. 
Methods: Five different antibiotics (cefazolin, clindamycin, linezolid, oxacillin, 
vancomycin) were stored, both as pills and as solutions, at -80°C, -20°C, 4°C, 20°C 
and 37°C; in addition, bone chips impregnated with cefazolin and vancomycin were 
stored at -80°C and -20°C. After 1 month, 6 months and 1 year, the activity of the 
antibiotics against Staphylococcus epidermidis was measured using an inoculated agar. 
The diameter of the S. epidermidis-free zone was taken as a measure of antibiotic 
activity. In a separate experiment, in vitro dose–response curves were established for 
bone chips impregnated with cefazolin and vancomycin solutions at five different 
concentrations. Finally, the maximum absorbed amounts of cefazolin and vancomycin 
were established by impregnating 1 g of bone chips with 5 ml of antibiotic solution. 
Results: A decrease of the S. epidermidis-free zone was seen with oxacillin and 
cefazolin solutions stored at 37°C for 1 month, with vancomycin stored at 37°C for 
6 months and with cefazolin and oxacillin solutions stored at 20°C for 6 months. 
The activity of the other antibiotic solutions, pills and impregnated bone chips was 
not affected by storage. The in vitro dose–response curves show that the free-zone 
diameter increases logarithmically with antibiotic concentration. The absorbed 
antibiotic amount of one gram bone chips was determined. 
Conclusions: Storage of antibiotics in frozen form or storage of antibiotic pills 
at temperatures up to 37°C for 12 months does not affect their activity. However, 
storage of antibiotic solutions at temperatures above 20°C does affect the activity of 
some of the antibiotics investigated. The in vitro dose–response curve can be used 
to determine the optimal concentration(s) for local application. It provides the 
opportunity to determine the antibiotic content of bone chips, and thus the amount 
of antibiotics available locally after application.
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BACkgRound 
Infection is one of the most devastating adverse events following joint replacement 
surgery. Deep infection rates in primary hip replacement surgery are around 0.5% to 2%. 
These infections result in a reduced quality of life [1, 2]. The patient often needs several 
re-operations, and if surgical debridement is not sufficient a Girdlestone situation is 
created; the patient then has to function without prosthesis for three to six months, which 
markedly limits physical activity. Furthermore, the hospitalisation costs for an infected 
patient are about 3.7 times those for a similar, uninfected patient [1]. 
Bone impaction grafting (BIG) for joint replacement surgery has been used with 
satisfactory results in clinical practice, for acetabular reconstructions since 1979 and for 
femoral reconstructions since 1987 [3-10]. With BIG, first the segmental bone defects 
in acetabulum and femur are restored with metal meshes. Next, these defects are filled 
with tightly impacted morselized cancellous bone chips in combination with a cemented 
prosthesis. Osteoclasts will resorb necrotic graft remnants and osteoblasts will form new 
woven bone. This remodelling of newly formed bone into its characteristic structure will 
lead to the biological repair of the defect following surgery [11].
Surgery with BIG is more complex and time-consuming than primary hip surgery which 
may contribute to a higher infection rate in hip revision surgery (percentages ranging from 
2.0% to 2.5% [12-14]). BIG creates an avascular area where local circulation is disrupted. 
If infections arises, this may prevent antibiotics that are administered systemically to 
reach the infected bone [15]. In addition, the formation of a biofilm on the surface of 
the implant renders systemic antibiotics less effective [16].
Bone cements containing antibiotics were developed to solve this problem. These cements 
may serve as a drug delivery system and prophylaxis against infections as they make it 
possible to achieve higher local drug concentrations. However, controversy exists on 
the efficacy of the antibiotic-containing cements [17]. Probably 90% of the antibiotics 
contained in the cement is never released [18]. Only when cracks are formed in the cement 
layer will a small, sub-inhibitory amount of antibiotics be released into the surrounding 
tissue. This release can continue for years, potentially inducing resistance. [18]. 
Several studies have shown that morselized allograft bone, which is used not only in 
BIG but also in other surgeries, can be made to act as a carrier for antibiotics, either by 
impregnating the bone grafts with various antibiotic solutions [19-23], or by mixing 
them with antibiotic powders [24, 25]. Although these studies showed, in vitro as well 
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as in vivo, that bone impregnated with antibiotics can be used effectively as prophylaxis 
against infections, they did not establish the concentration of antibiotic present in the 
bone after impregnation and how much was released locally. Furthermore, no correlation 
of antibiotic concentration and zone of inhibition was reported of the antibiotics used in 
combination with bone chips. Finally, allograft bone is stored at a bone bank at -80°C, 
then thawed in the operating room. In the impregnation studies, all the antibiotics were 
added to the thawed bone, immediately before use. It is thus unknown whether the 
antibiotics can be added before freezing without affecting their activity. 
Based on this we investigated if storage of antibiotics and antibiotic-loaded bone grafts 
at different temperatures affects their activity. The correlation between antibiotic 
concentration and zones of inhibition for the bone/antibiotics composites was analysed. 
The results permit us to develop a standardized bone bank product in which the amount 
of antibiotics present on the bone chips, and therefore the amount of antibiotics released 
locally from the bone, will be known. 
meThodS 
measurement of activities
For all tests performed in this study, the following method was used:
Antibiotic pills, antimicrobial susceptibility test disks (Oxoid) with antibiotic solution 
dripped onto the disks and bone chips impregnated with antibiotic solution were placed 
on an inoculated iso agar (cefazolin, clindamycin, linezolid or vancomycin) or an 
inoculated Mueller Hinton agar (oxacillin). Bone chips were placed in a hole of 10 mm 
diameter punched into, but not through, the agar and then covered with 25 μl saline 
dripped onto them. 
All agars were inoculated with 0.5 McFarland ATCC 12228 Staphylococcus epidermidis 
since this organism is one of the main pathogens colonizing biomaterials [26]. After 
storing the iso agars at 37°C and the Mueller Hinton agars at 30°C for 18–24 hours, the 
zones of inhibition were measured. 
Antibiotic pills from the routine clinical lab were used as controls. The zone of inhibition 
of these pills is comparable to that of 10 μl antibiotic solution and that of chips freshly 
impregnated with 10 μl antibiotic solution. 
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Cefazolin, clindamycin, linezolid, oxacillin and vancomycin were used in this study, all 
antibiotics against gram stain positive micro-organisms, the main cause for orthopaedic 
infections. Oxacillin is the preferred treatment for systemic staphylococcal infections and 
in case of penicillin hypersensitivity the others are used (mainly cefazolin or clindamycin). 
For prophylaxis cefazolin or clindamycin are preferred and in case of infection with 
methicillin resistant Staphylococcus aureus (MRSA) vancomycin is used. In this way 
all important antibiotics against these gram stain positive micro-organisms were tested. 
The concentrations used for the tests are the concentrations used in the whole range of 
clinical situations: systemic or local infection and prophylactic use. In addition, high 
concentrations were used to determine local concentration limits. 
Five different storage temperatures were used in the experiments. -80°C and -20°C are 
storage temperatures for allograft bone in bone banks. 4°C and 20°C are commonly used 
storage temperatures in the laboratory and 20°C is the temperature of the operation 
room. 37°C was included so as to investigate antibiotic stability at higher temperature 
and because this temperature is body temperature. 
Storage of antibiotic pills
Pills of five different antibiotics – cefazolin 60 μg, clindamycin 25 μg, linezolid 30 μg, 
oxacillin 1 μg and vancomycin 70 μg – were stored at five different temperatures. For each 
antibiotic, nine pills of each antibiotic were stored in a closed tube at each temperature. 
After 1 month, 6 months and 1 year of storage, three pills of each antibiotic were brought 
to room temperature and placed on an agar to determine the inhibition zone of the pills. 
Storage of antibiotic solutions
Five different antibiotic solutions  – cefazolin 6.0  mg/ml, clindamycin 2.5  mg/ml, 
linezolid 3.0 mg/ml, oxacillin 0.1 mg/ml and vancomycin 7.0 mg/ml – were stored at five 
different temperatures. For each antibiotic solutions, 9 tubes of 1 ml, were stored at each 
temperature. After 1 month, 6 months and 1 year of storage, three tubes of each antibiotic 
solution were brought to room temperature and 0.10 μg of each antibiotic solution was 
dripped onto a antimicrobial susceptibility test disk which was then placed on an agar. 
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Storage of bone chips impregnated with antibiotic solutions
60 tubes, each containing 0.10 g of bone chips from a human morselized femoral head, 
were impregnated with 60 μg/10 μl cefazolin solution for ten minutes, then 30 were stored 
at -80°C and 30 at -20°C. Similarly, 60 tubes with 0.10 g bone chips each were impregnated 
with 70 μg/10 μl vancomycin and 30 were stored at -80°C and 30 at -20°C. Other storage 
temperatures were not tested, since bone allografts cannot be used for transplantation 
after storage at temperatures above  -20°C for more than one month. After 1 month and 
6 months of storage, 20 tubes each of the cefazolin- and the vancomycin-impregnated 
bone chips (ten tubes from -80°C and 10 tubes from -20°C storage) were thawed and 
placed on iso agars (Figure 5.1).
Correlation of antibiotic concentration and zone of inhibition of bone 
impregnated with vancomycin and cefazolin
Five different cefazolin solutions and five different vancomycin solutions were used to 
impregnate bone chips from a morselized femoral head and to determine the correlation 
of antibiotic concentration and zone of inhibition. The concentrations were chosen so as to 
Figure 5.1 Bone chips on an inoculated iso agar.
79
Im
pregnation of bone chips w
ith antibiotics: an in vitro study
Chapter 5
exceed the minimal inhibitory concentration, and similar to that of the control pills from 
the clinical routine lab (cefazolin 60μg and vancomycin 70μg). Cefazolin: 0.5 μg/10 μl, 
2.5  μg/10  μl, 10  μg/10  μl, 60  μg/10  μl and 100  μg/10  μl; vancomycin: 0.5  μg/10  μl, 
2.5 μg/10 μl, 10 μg/10 μl, 70 μg/10 μl and 100 μg/10 μl. For each concentration, ten 0.10 g 
bone chips were impregnated at room temperature for ten minutes and placed on agar 
as described above; the mean diameter of the free zone was measured, and the antibiotic 
quantity was correlated to the zone of inhibition. 
determination of the maximum amount of antibiotics absorbed by bone 
chips
One gram of bone chips from a morselized femoral head was impregnated with 5 ml of 
cefazolin or vancomycin solution. The maximum absorbed amount was then calculated 
based on the correlation between antibiotic concentration and zone of inhibition 
determined earlier.
Chips were impregnated with four different cefazolin solutions (1000 μg/5 ml, 750 μg/5 ml, 
500 μg/5 ml and 250 μg/5 ml) and with four different vancomycin solutions (5000 μg/5 ml, 
2500 μg/5 ml, 1000 μg/5 ml and 250 μg/5 ml). After ten minutes of impregnation the 
remaining solution was poured off. 0.10 gram was taken off the impregnated 1 gram and 
placed on an inoculated agar; this was repeated five times. The zone of inhibition around 
the chips was measured. Matching this zone to a zone of inhibition in the correlation 
analysis performed earlier yielded the matching amount of antibiotics and thus the 
maximum amount of antibiotic that can be absorbed at this concentration. In a repeat 
test, after the antibiotic solution was poured off the bone chips were rinsed twice with 
5.0 ml saline in order to remove any antibiotic solution remaining on the surface of the 
bone chips; thus, the real amount absorbed by the bone chips was calculated.
ReSuLTS
Storage of antibiotics
No differences were seen, compared to controls, in the zone of inhibition for cefazolin, 
vancomycin, linezolid and clindamycin pills that had been stored at -80°C, -20°C, 4°C, 
20°C and 37°C for 1 month, 6 months and 1 year. Also, no differences in response at any 
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of these temperatures were found for clindamycin and linezolid solutions that had been 
stored for 12 months. 
Oxacillin pills stored at 4°C for 12 months showed a decreased zone of inhibition 
compared to controls. Oxacillin solutions showed a decreased zones of inhibition after 
1 month of storage at 37°C and after 6 months of storage at 20°C. No zone of inhibition 
could be found after 12 months of storage at 20°C and after 6 months of storage at 37°C 
(Figure 5.2). At other temperatures, no differences in the zone of inhibition were seen 
compared to controls.
Vancomycin solutions stored at 37°C for 6 months showed a decreased zone of inhibition, 
while the zone of inhibition was not affected after 1 month of storage at this temperature 
(Figure 5.3). At -80°C, -20°C and 4°C no differences were visible compared to controls as 
was the case for vancomycin solutions stored at 20°C for 6 months; however, 12 months 
at 20°C did result in a decreased zone of inhibition (Figure 5.3). 
For cefazolin solutions, the zone of inhibition was decreased when compared to controls 
after storage at 37°C for 1 month and at 20°C for 6 and 12 months. No zone of inhibition 
could be seen after 6 and 12 months of storage at 37°C (Figure 5.3).
Figure 5.2 Storage of oxacillin pills (1 μg) at 4°C or oxacillin solutions (0.1 mg/ml) at 20°C 
and 37°C for 1 month, 6 months and 12 months compared to controls.
0
5
10
15
20
25
30
35
40
4°C (pills) 20°C (solutions) 37°C (solutions) Control
Zo
ne
 o
f i
nh
ib
iti
on
 (m
m
)
Temperature (°C)
1 month 6 months 1 year
81
Im
pregnation of bone chips w
ith antibiotics: an in vitro study
Chapter 5
Storage of bone chips impregnated with antibiotics
Bone chips impregnated with vancomycin or cefazolin, stored at -20°C and -80°C for 
6 months did not show a difference in zone of inhibition when compared to controls 
(Figure 5.4).
Correlation of antibiotic concentration and zone of inhibition of bone 
chips impregnated with vancomycin and cefazolin
The correlation of antibiotic quantity and zone of inhibition of bone chips impregnated 
with cefazolin and vancomycin is presented in Figure 5.5. A curve was fitted between 
the quantity of antibiotic and diameter of inhibition zone measured. With increasing 
antibiotic quantity, the zone of inhibition increases logarithmically.  
determination of the maximum absorbed amount  
Table 5.1 represents the results of the impregnating bone chips with 5 ml cefazolin or 
vancomycin solution. The zones of inhibition of 0.10 g bone chips impregnated with 5 
Figure 5.3 Storage of cefazolin solutions (6.0 mg/ml) or vancomycin solutions (7.0 mg/ml) 
at 20°C and 37°C for 1 month, 6 months and 12 months compared to controls.
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Figure 5.4 Storage of bone chips impregnated with cefazolin solution (6.0 mg/ml) or 
vancomycin solution (7.0 mg/ml) at -80°C and -20°C for 1 month and 6 months compared to 
controls.
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Table 5.1 Impregnation of bone chips with cefazolin and vancomycin solutions
 Antibiotic Rinsing with 0.9% 
saline, +/–
Antibiotic content 
of impregnation 
fluid (μg/5 ml)
Mean diameter of 
S. epidermidis-free 
zone (mm)
Mean antibiotic 
content of 1.0 g of 
bone chips (μg)
Cefazolin + 1000 28.0 ± 1.2 32
+ 750 23.6 ± 1.3 15
+ 500 23.0 ± 1.2 13
+ 250 19.6 ± 0.5 7
– 1000 32.4 ± 0.9 105
– 750 31.8 ± 0.8 92
– 500 29.0 ± 2.4 44
– 250 28.6 ± 0.5 39
Vancomycin + 5000 23.2 ± 0.5 214
+ 2500 22.0 ± 1.0 212
+ 1000 17.8 ± 1.1 204
+ 250 7.6 ± 6.9 178
– 5000 24.2 ± 0.8 215
– 2500 23.6 ± 1.1 214
– 1000 22.8 ± 3.3 212
– 250 16.0 ± 0.7 201
Antibiotic quantity of 1.0 g bone chips, with and without rinsing of the bone chips, is calculated using 
the regression analysis of the antibiotic solution (Figure 5.5).
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ml antibiotic solution (and rinsed with saline twice) are related to antibiotic quantity in 
Figure 5.5 (represented by the squares). The associated quantity of antibiotic present in 
0.10 g of chips can then be read from the figure, and from this, the antibiotic content of 
1.0 g bone chips is determined (Table 5.1). 
dISCuSSIon
Storage of antibiotics
The effects of different storage temperatures on antibiotics were studied. In addition, we 
examined the reaction to freezing of bone chips impregnated with antibiotics. It can be 
concluded that storage at -80°C and -20°C does not affect the activity of antibiotics for 1 
Figure 5.5 Regression analysis of bone chips impregnated with antibiotic solutions. 
Squares represent the inhibition zones for 0.10 g of bone chips taken from 1.0 g of bone chips 
impregnated with 5 ml of antibiotic solution and rinsed with saline twice; the fitted curves 
yield the corresponding antibiotic content.
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year, and that, of bone chips impregnated with cefazolin and vancomycin up to 6 months. 
This shows that bone chips can be impregnated with antibiotics before storage in a bone 
bank. This makes surgery easier, safer and less time-consuming for the orthopaedic 
surgeon since they do not have to add the antibiotics during the procedure and faults 
can be avoided this way.
Correlation of antibiotic quantity and zone of inhibition of bone impreg-
nated with vancomycin and cefazolin and determination of the maximum 
absorbed amount
Numerous studies have concluded that morselized bone can act as a carrier for antibiotics 
[19-25]. These studies show that prophylactic use of bone chips impregnated with 
antibiotics can be effective. However, the amount of antibiotics present in the bone 
chips after impregnation was not determined in any of these studies, while antibiotics 
are effective only if their concentration is high enough to eradicate bacteria. Our study 
investigated the reactions, in vitro, of S. epidermidis to bone chips impregnated with 
cefazolin and vancomycin solutions. Correlation of antibiotic quantity and zone of 
inhibition of bone chips impregnated with the antibiotic solutions show that increasing 
amounts of cefazolin and vancomycin increase the zone of S.  epidermidis inhibition 
logarithmically. At therapeutic concentrations, the correlation analysis is a good 
reproduction of reality, even though the zones of inhibition at high concentrations are 
probably not very reliable. The question can be asked whether it is necessary to use 
the maximum local amounts of antibiotics obtainable. It is apparent from figure 5 that 
increasing the antibiotic amount to above approximately 20 μg per 0.1 gram bone chips 
will not significantly increase the zone of inhibition. This suggests that approximately 
20 μg per 0.1 gram bone chips is sufficient to eradicate the bacteria in vitro. 
Local antibiotic therapy has to meet several other requirements in addition to that of 
sufficient concentration at the site of infection. Drug delivery has to be controlled in order 
to ensure that known adverse drug effects like deafness or renal failure are prevented 
[22]. Also, antibiotic concentrations should not be cytotoxic to osteoblasts or bone 
tissue. According to Edin, Miclau et al. [27], local levels of vancomycin of <1000 μg/ml 
do not affect osteoblast replication. Cefazolin at concentrations of 200 μg/ml decreases 
cell replication, but does not affect the replication of osteoblasts at levels of 100 μg/ml. 
The concentrations of cefazolin and vancomycin solutions in our study were neither 
toxic to osteoblasts nor able to cause systemic side effects, but were very effective against 
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S.  epidermidis in vitro. However, the concentrations needed in prophylaxis against 
infections might be different. 
To our knowledge, no studies have investigated how long high local antibiotic 
concentrations must be sustained to obtain effective infection prophylaxis. The prolonged 
release of antibiotics from antibiotic-containing bone cement did not protect against late 
hematogenous infections [28]. For prevention, a high local antibiotic concentration will 
be effective, even if this is only for a short time; one or two days, or even a few hours, 
can be sufficient. As long as the concentration of vancomycin and cefazolin is above the 
minimal inhibitory concentration (MIC) for S. epidermidis, it will have the maximum 
effect. The concentrations used in this study are well above MIC; taking into account 
the half-life of these antibiotics, they will stay above MIC – and be effective – for at least 
8 to 10 hours. For therapeutic use, the carrier may be more effective if the antibiotic 
concentration is high for a longer period, preferably for 2–4 weeks. The diffusion of the 
antibiotic into the infected tissues takes time, as does the killing process of the bacteria.
Witso et al. [22] have shown that the elution profile from bone chips is different for 
different antibiotics. The elution profile of cephalosporins (cefazolin) shows a high initial 
release with rapid decay. After three days, all the antibiotics are eluted from the bone 
chips, leaving no subinhibitory amount of drug that could induce resistance. Therefore, 
cefazolin is a good choice for local prophylaxis. However, cephalosporins carry a small 
risk of hypersensitivity[29]. Vancomycin is another good choice for impregnating bone 
chips; it has low resistance and allergy rate and, like cefazolin, is very effective against 
S. epidermidis and Staphylococcus. aureus, the main pathogens colonizing biomaterials 
[26]. The elution profile of vancomycin is not as steep as that of cefazolin, with some 
elution even after seven days.
From past experience, it is likely that it will only be a matter of time before bacteria 
develop a mechanism of resistance against any new locally applied antibiotic. Therefore, 
further research into the use of combinations of antibiotics, i.e. multidrug targeting, is 
in order [30]. 
Differences between rinsing with saline and not rinsing the bone chips after impregnation 
were also studied. We hypothesized that rinsing the bone chips would remove antibiotic 
solution remaining on the surface of the chips. With cefazolin, bone chips rinsed with 
saline twice had a smaller free zone than bone chips that were not rinsed. This difference 
was not found with vancomycin. The activity of the antibiotics against S. epidermidis 
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was still evident after rinsing the bone chips with saline, and high enough to eradicate 
the bacteria. It can therefore be concluded that the antibiotics are absorbed by the bone 
chips and the activity does not stem from antibiotic solution remaining on the surface 
of the bone chips. In vivo research is needed to assess the clinical value of antibiotics-
impregnated bone chips. 
Conclusions 
In conclusion, storage at -80°C and -20°C of antibiotic solutions, antibiotic pills and bone 
chips impregnated with cefazolin and vancomycin does not affect the activity of the drugs 
for at least one year. It is therefore possible to impregnate bone chips with antibiotics and 
store them in a bone bank at one of these temperatures. Also, storage of antibiotic pills 
at temperatures up to 37°C for 12 months does not affect their activity. However, storage 
of antibiotic solutions at temperatures above 20°C does affect the activity of some of the 
antibiotics investigated.
Based on the correlation of antibiotic quantity and zone of inhibition for cefazolin and 
vancomycin, optimal concentration(s) for impregnation of bone chips were determined. 
The correlation provides the opportunity to determine the antibiotic content of the bone 
chips so that a safe and reproducible bone bank product can be developed. 
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ABSTRACT
Background: Intraoperative bacterial contamination has been related to the occur-
rence of periprosthetic infection. 
Aim: It was hypothesized that a reduced frequency of door-openings leads to a 
reduced number of CFUs during surgery. 
Methods: During 70 hip revision surgeries operation circumstances were monitored 
by measuring numbers of particles and CFUs. The number of door-openings, the 
number of people and the duration of the surgery were registered; the number of 
particles and number of CFUs/m3 were measured. Logistic regression analysis was 
used to determine the relation between the different parameters measured during 
surgery and the number of CFUs/m3. Medical files of all patients were reviewed to 
assess the occurrence of an infection post-operatively.
Findings: An average number of 78 (±83) CFUs/m3 was measured. An average 
number of 4.5 (±4.8) door-openings/hour was found. Mean operation time was 151 
(±47) minutes and the average number of people present during the surgery was 8 
(±1.5). No significant relation was found between the number of door-openings 
and the number of CFUs/m3 during surgery (p=0.08; OR 0.14 (0.02–1.24)). Other 
parameters were not associated with the number of CFUs/m3 during the hip revision 
surgeries. Mean follow-up of all patients was 28 months (±14.6). One patient 
developed an infection postoperatively (1.4%).
Conclusion: In conclusion, no significant relation was found between the number 
of door-openings and the variation of CFUs/m3. Moreover, the number of people 
present during surgery and the time of the surgery were not related to the variation 
of CFUs/m3.
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InTRoduCTIon 
Total hip arthroplasties (THAs) are very successful and frequently performed surgeries 
[1]. Despite the success of these surgeries, infection occurs in approximately 0.5 to 3% 
of all primary THAs and in 4 to 6% of all revision THAs [1, 2]. Infection is a potentially 
devastating complication; patients may require further surgery, additional nursing 
care and prolonged hospital stay. Moreover, it might result in a reduced quality of life 
and more physical limitations [3, 4] Furthermore, the costs of hospitalisation of an 
infected patient are about 3 to 4 times higher than those of an uninfected patient [4]. 
Intraoperative bacterial contamination has been related to the occurrence of periprosthetic 
infection [5]. Intraoperative contamination of the wound may occur with the patient’s 
skin flora or with the commensal flora of the theatre personnel through instruments 
and other materials [6]. In addition, studies have shown that most airborne bacteria 
reach the wound area via the hands of the surgical personnel or by the instruments 
used [7, 8]. 
Several studies have investigated the presence of airborne bacteria in the operating 
theatre, factors that influence their numbers, and their role in intraoperative infection, 
all with different conclusions [5, 9-13]. To minimize periprosthetic infection, it was 
proposed by the Hospital Infection Society Working Party on Infection Control 
in Operating Theatres (HISWPICOT) that during high-risk operations, such as 
orthopaedic implant surgery, the number of colony forming units (CFUs) in air should 
not exceed 10 CFU/m3 at 30 cm distance from the wound and not exceed 20 CFUs/m3 
directly around this zone [14]. In non high-risk surgery, a maximum of 180 CFUs/m3 is 
allowed. The advice of the HISWPICOT is also adopted in The Netherlands, however 
strict rules on maximum CFUs or rules on discipline in the operating theatre are not 
available. 
In this study the air quality in the operating theatre during hip revision surgery and the 
influence of door-openings on air quality were investigated by measuring the number 
of CFUs/m3. It was hypothesized that minimizing the number of door-openings would 
lead to reduced numbers of CFUs during surgery.
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MATeRIAlS And MeThodS 
Setting
This observational study evaluated air quality in the operating room during revision hip 
arthroplasties and was embedded in another study on bone grafts [15]. Hence, consecutive 
revision hip surgeries with bone impaction grafting (BIG) were included. Between 
February 2009 and December 2011, 70 hip revision surgeries with BIG were included.
The study was performed at the Departments of Orthopaedics at the Radboud University 
Nijmegen Medical Center in Nijmegen, and the Reinier de Graaf Hospital in Delft, the 
Netherlands. In Nijmegen, 59 surgeries were monitored, the remaining 11surgeries in 
Delft. The study was approved by the local Medical Ethics Committees and written 
informed consent was obtained from all patients. 
Both operating theatres have turbulent-flow ventilation systems equipped with HEPA 
filters, which are 99.97% efficient in removing airborne particles of 0.3 mm or larger. In 
Nijmegen, the HEPA filters are replaced every 6 months and maintenance work on the 
system is carried out periodically. The operating room is under positive pressure in relation 
to the adjacent rooms (5 Pa), air temperature and humidity are set respectively at 18˚C and 
56–60%. In Delft, the HEPA filters are replaced every 12 months. The operating room is 
under positive pressure in relation to the adjacent rooms (15 Pa), air temperature is set at 
18˚C and humidity at 50–65%. In Delft, exhaust body suits were used by the operating team. 
Factors that may influence the air quality were registered, including the number of door-
openings, the number of sterile and non-sterile people, and the duration of the surgery. 
Air quality measurements
The number of particles in the air was measured with an Airborne Particle Counter (APC 
Plus, Kregliner Europe, Antwerp, Belgium), every 10 minutes for 1 minute during the 
surgery at a distance of approximately 1.5 meter of the wound. The APC Plus counter 
was positioned horizontally at wound height and directed towards the wound. Particles 
were detected in four diameter thresholds: >0.3 µm, >0.5 µm, >1.0 µm, and >5.0 µm. 
The number of CFUs/m3 was measured 4 times during surgery: directly after incision, 
directly after opening of the container of the allograft bone, at the time this bone graft 
was first used in the procedure, and again 10 minutes later. 
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At the same position as the Airborne Particle Counter, 200 l of air with an airflow rate 
of 100 l/min was aspirated with the High Flow Microbial Airborne Sampler (RCS High 
Flow, Kregliner Europe, Antwerp, Belgium) containing an RCS-strip with Tryptic Soy 
Agar (TSA, Kregliner Europe, Antwerp, Belgium). A sedimentation plate (TSA, Kregliner 
Europe, Antwerp, Belgium) was placed on the instrument table for 1 hour from the 
moment of opening the container of the allograft bone. The numbers of CFUs on the 
RCS-strips as well as on the sedimentation plate were counted manually after 48 h of 
incubation at 30˚C. The number of CFUs on the RCS-strips and the sedimentation plates 
were converted to number of CFUs/m2/hour and number of CFUs/m3, respectively. 
Follow-up
The medical files of all patients were reviewed, including clinical, radiological, and 
laboratory findings, to assess the occurrence of an infection post-operatively. 
data analysis
Outliers in CFUs/m3 were defined as values higher as the 95th percentile and subsequently 
replaced by the 95th percentile value. To discriminate between numbers of CFUs/m3 at 
the four different time points during the hip revision surgery, a Friedman test was used. 
Since no differences between the four different time points could be measured, mean 
CFUs/m3 for each operation was calculated. 
Logistic regression analysis was performed to determine the relation between the different 
variables measured during surgery and the number of CFUs/m3. According to the proposal 
of the HISWPICOT, 20 CFUs/m3 is the maximum acceptable number of CFUs during high-
risk operations. Therefore, the variable CFUs/m3 was dichotomized in either ‘acceptable’ 
(≤20 CFUs/m3) or ‘not acceptable’ (>20 CFUs/m3). First, univariate logistic regression 
analyses were performed for the number of door-openings, operation time, number of 
people present during surgery (total number as well as the number of people non-sterile), 
hospital, the number of particles measured during surgery and the number of CFUs/m2/
hour measured with the sedimentation plate. A normal distribution could not be assumed 
for the number of particles, the number of door-openings, the number of people present 
during surgery (total number as well as the number of people non-sterile) and the number 
of CFUs/m2/hour measured with the sedimentation plate. The number of particles were log 
transformed to obtain values with a normal distribution. The other variables for which a 
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normal distribution could not be assumed were dichotomized into ‘low’ (lower or equal to 
the mean) and ‘high’ (higher than the mean). Variables that were associated with the outcome 
in univariate analyses (p<0.20) were included in multivariate logistic regression analyses. 
All statistical analyses were performed using IBM SPSS statistics 20.0 (Chicago, Illinois). 
P-values <0.05 were considered statistically significant.
ReSulTS
Air quality during hip revision arthroplasties
One surgical procedure was excluded because the patient was intra-operatively resus-
citated, resulting in severe violation of all sterility protocols. Therefore, 69 hip revision 
surgeries were analysed
The results of the 69 hip revision arthroplasties are summarized in Table 6.1. An average 
number of 4.5 (±4.8) door-openings/hour was found. Mean operation time was 151 (±47) 
minutes and the average number of people present during the surgery was 8 (±1.5). The 
mean number of CFU/m3 was 78 (±83), no differences could be found between numbers 
of CFUs/m3 at the four different time points during surgery (p=0.2). During 14 surgeries 
an acceptable number (according to HISWPICOT) of less than 20 CFUs/m3 was measured 
and during 55 surgeries this number was exceeded. 
Univariate logistic regression showed that the number of door-openings and mean 
number of particles of >0.3 µm >0.5 µm and >1.0 µm had p-values <0.20 (Table 6.1). 
These variables were included in multivariate logistic regression. Operation time, number 
of people present during surgery and CFU/m2/hour measured with the sedimentation 
plate were not associated with the number of CFUs/m3 during the surgery. The variable 
‘hospital’ (Nijmegen vs. Delft) was excluded from the analyses because one of the cells 
in the contingency table was zero. In other words, there were not enough observations 
to draw any conclusions for this variable.
 Because of multicollinearity between mean number of particles of >0.3 µm, >0.5 µm and 
>1.0 µm, only the results of >0.5 µm were used for multivariate analysis since they were 
most significant after univariate analysis (Table 6.1). Multivariate analysis showed that 
there was no significant relation between number of door-openings and the number of 
CFUs/m3 during surgery (p=0.08). Moreover, the mean number of particles >0.5 µm was 
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not associated with the number of CFUs/m3 during the hip revision surgeries (p=0.16). 
Odds ratios were 0.14 (0.02–1.24) and 1.67 (0.82–3.43) for door-openings/hour and mean 
number of particles of >0.5 µm, respectively.
Follow-up
Mean follow-up (FU) of all patients was 28 months (±14.6). Mean age at operation was 
67.4 (±10.9) years. Of the patients, 56% was female. 
One patient developed an infection postoperatively (1.4%). This infection was caused 
by coagulase negative Staphylococcus (CoNS) and Enterobacteriae. Number of CFUs/
m3 during the surgery was 11.3 and numbers of door-openings/hour was 1.6 in this case. 
dISCuSSIon
In this study we measured the numbers of CFUs during 69 hip revision arthroplasties in 
combination with BIG. It was hypothesized that a reduced frequency of door-openings 
leads to a reduced number of CFUs during surgery.
Table 6.1 Overview of variables measured during 69 revision hip arthroplasties and results 
of univariate and multivariate logistic regression analyses
Variable Mean (± SD) Univariate LR
odds ratio 
(95% CI)
p-value Multivariate LR
odds ratio 
(95% CI)
p-value
Number of door-
openings/hour1
4.5 ± 4.8 0.12 (0.014–0.95) 0.04 0.14 (0.02–1.24) 0.08
Number of people 
present during 
surgery1
7.8 ± 1.5 0.82 (0.23–2. 98) 0.77
Particles >0.3 µm# 5464 ± 6674 1.62 (0.87–3.0) 0.13
Particles >0.5 µm# 547 ± 756 1.96 (0.99–3.93) 0.06 1.67 (0.82–3.43) 0.16
Particles >1.0 µm# 67 ± 74 1.79 (0.77–4.18) 0.18
Particles >5.0 µm# 4.2 ± 2.5 0.55 (0.19–1.57) 0.26
CFU/m2/hour1 2276 ± 4196 0.54 (0.16–1.84) 0.32
Operation time (min) 151 ± 47 0.99 (0.98–1.01) 0.32
Number of people 
non-sterile1
4.4 ± 1.3 1.07 (0.29–3.92) 0.92
# Number of particles was log transformed. 1 Variables were dichotomised into ‘low’ (lower than the mean) 
and ‘high’ (higher or equal to the mean). 
LR=logistic regression.
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We did not find a significant association between door-openings and CFUs/m3 in our 
study (p=0.08). The odds ratio of door-openings/hour after multivariate analysis was 
0.14 (0.02–1.24), meaning that if the number of door-openings/hour increases to more 
than 4.5, the risk of a number of CFUs/m3 of more than 20 (the HISWPICOT criterion), 
increases 7 times (1/0.14). The number of surgeries included in our study was probably 
not high enough to detect a significant relation. Moreover, the 95% CI of the odds ratio 
of door-openings/hour varies greatly, probably because the results of CFUs/m3 varied 
throughout the surgeries performed. This variation in CFUs/m3 between the different 
surgeries is in accordance with the results of previous reports [13, 16].  
Only if strictly necessary, doors were allowed to be opened in both hospitals. This resulted 
in a very low average number of door-openings/hour (4.5±4.8). This average number is 
very low when compared to other studies [16-21]. This might also explain the absence of 
a significant association between door-openings and CFU/m3. Other studies also reported 
no significant contribution of door-openings to the number of CFUs/m3 [13, 22]. However, 
Andersson et al. [23], found that 34% of the variance in CFUs/m3 could be explained by 
door-opening during the surgery, although the number of door-openings per hour in 
their study was much higher when compared to our study. A relation between increased 
number of door-openings and the risk of infection has been suggested by several authors 
[18, 20, 21], however could not be confirmed by the present study.
The HISWPICOT proposed a maximum of 20 CFUs/m3 at a distance of more than 30 cm 
of the wound during implant surgery. When this criterion of <20 CFUs/m3 was taken as 
reference, 14 out of 69 operations did meet this criterion. Moreover, in all 69 hip revision 
surgeries performed, only during 2 operations the proposed criterion of <10 CFUs/m3 
(at a distance of 30 cm of the wound) was met. Air quality measurements performed by 
Andersson et al. [16] and by Stocks et al. [13] during joint arthroplasties also exceeded the 
recommended level of <10 CFUs/m3, although their mean values were lower compared to 
our results. As is stated by Dharan and Pittet [24], it is not easy to achieve these limits as 
various factors influence the bio burden during a surgical procedure. In contrast, Ahl et 
al. [25] did find mean results which not exceeded the proposed limits. They even stated 
that, when wearing body exhausted clothes, it is possible to achieve numbers <1 CFUs/m3. 
Ritter [26] suggested to reduce the number of people present during the surgery and to 
reduce the operating time to decrease the number of bacteria in the air. Moreover, Ong 
et al. [27] concluded that procedure duration is a significant risk factor for infection. 
However, we were not able to find a relation between the numbers of CFUs/m3 and 
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the operation time or number of people in the operating room. The number of people 
during the hip revision surgeries in our study was constantly high, since both hospitals 
were teaching hospitals, which might explain the absence of a relation between number 
of people and the numbers of CFUs/m3. Andersson et al. [16] stated that the duration of 
the surgery in relation to the total CFU level is of clinical relevance, since the total CFU 
level increases with increasing duration of surgery, thereby exposing the wound to an 
increased total number of CFUs and increasing the risk of infection. 
No relation between particles, CFUs/m3 and CFUs/m2/hour on the sedimentation plate 
could be found in this study. Cristina et al. [28] also did not reveal any correlation between 
particles and numbers of CFUs. They therefore conclude that microbiological monitoring 
remains the most suitable method for evaluating the air quality in the operating theatre. 
In contrast, it was stated by Friberg et al. [29] that sedimentation plates are the most 
realistic indicator of airborne bacterial contamination in the operating room. However, 
no international consensus on what method to be used for air monitoring is available at 
this moment, there is still debate on the sampling techniques to be used, their frequency 
of application and even on the usefulness of such checks and controls [30].
One patient developed an infection in our study. Remarkably, the number of door-
openings during this procedure as well as the number of CFUs/m3 was low. 
In conclusion, no significant relation was found between the number of door-openings 
and the number of CFUs/m3. The proposed maximum of <20 CFUs/m3 during high risk 
operations by the HISWPICOT was exceeded in this study, although only one patient 
developed an infection postoperatively. Moreover, the number of people present during 
surgery and the time of the surgery were not related to the variation of CFUs/m3. Particle 
measurements and the number of CFUs/m2/hour measured with the sedimentation plate 
did not correlate to the numbers of CFUs.
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ABSTRACT
Background: Dual-Energy X-ray Absorptiometry (DEXA) for femoral bone impac-
tion grafting and bone remodeling after hip revision surgery was evaluated in this 
study. Another goal of this study was to see whether DEXA can detect and quantify 
bony defects in the femur, before hip revision surgery. 
Methods: This study consisted of two parts; first part was a cadaver study in which 
10 femoral specimens from cadaver donors were used to determine bone loss of the 
femur before hip revision and to evaluate steps of hip revision arthroplasty with bone 
impaction grafting with DEXA. After each step a DEXA scan was made. The defect 
created in the femur was weighted and correlated to the bone mineral content and 
bone mineral density. Second part of this study was an observational pilot study in 
which bone mineral density (BMD) of the femur of 13 patients, 1 to 5 years after hip 
revision surgery with bone impaction grafting, was analysed with DEXA. 
Results: No correlation could be found between the weight of the created defects and 
the BMD- or BMC-differences in Gruen zone 7 (p=0.20 and p=0.28, respectively). 
Moreover, no correlation between the weight of the created defects and the BMD- 
or BMC-differences in Gruen zone 1 was found (p=0.60 and p=0.93 respectively). 
Repeatability for all DEXA scans was 1.0 and 0.99 for BMC and BMD respectively. 
12 patients were used for evaluation. Mean age was 71.9 (±9.5) years. Range of the 
postoperative scan intervals was 10–63 months after surgery. The average BMD of 
the revised hip was higher when compared to the BMD of the contralateral side. ICC 
was 0.923 for all first and second DEXA scans of the revised hip. When results of 
individuals with cerclage wires and meshes are excluded, the ICC of the BMD of the 
revised hip increased to 0.955. Contrary, when only the results of BMD of individuals 
with cerclage wires and meshes are analyzed, ICC dropped to 0.796.
Conclusion: Since cerclage wiring and meshes are frequently used during femoral 
revision with BIG, DEXA might not be suitable to monitor BMD after femoral 
revision surgery with BIG.
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BACkgRound 
Hip revision surgery is a challenge to orthopaedic surgeons and bone loss around the 
primary implant is one of the major problems [1]. Restoration of the bony defects can be 
done with bone impaction grafting (BIG). BIG for joint replacement surgery has been used 
with satisfactory results in clinical practice since 1979 for acetabular reconstructions and 
for femoral reconstructions since 1987 [2-9]. With BIG, first, in case of segmental bone 
defects, these defects in acetabulum or femur have to be restored with metal meshes. Next, 
the now cavitary defects are filled with tightly impacted morselized allograft cancellous 
bone chips in combination with a cemented new prosthesis. The allograft bone serves as 
a scaffold; new bone can grow into the allograft bone and the allograft bone is resorbed. 
The allograft bone chips are resorbed by osteoclasts and osteoblasts will form new woven 
bone. This remodelling of newly formed bone into its characteristic structure will lead 
to the biological repair of the defect following surgery [10]. From biopsies taken from 
the acetabular component of patients who had previous hip revision surgery with bone 
impaction grafting, it is clear that the allograft bone will be almost completely remodeled 
and incorporated into a new bony structure [11], although this might take several months 
or even years [12]. Moreover, histology of the bone after bone impaction grafting in hip 
revision surgery showed that this bone remodeling is slow and that bony healing after hip 
revision may not be predictable [13, 14] Absence of balance between the resorption of the 
allograft bone and the formation of new bone could contribute to stem migration [15].
To understand bone remodeling around primary prosthetic hip implants, several studies 
used Dual-Energy X-ray Absorptiometry (DEXA) [16-24]. DEXA measures bone mineral 
density (BMD) in a reproducible, precise and accurate manner and has low radiation 
exposure to the patient and low costs [23, 25]. Laursen et al. [26] studied experimental 
defects around acetabular components in human post mortem pelvis specimens. They 
concluded that DEXA scanning provides a sensitive measure of changes in bone mineral 
content (BMC) around cementless hemispherical metal-backed cups. However very few 
studies are known on DEXA and femoral revision surgery with BIG [27]. 
DEXA might be a tool for quantification of changes in bone content and bone remodeling 
after revision surgery. Therefore, the use DEXA for femoral bone impaction grafting and 
bone remodeling after hip revision surgery was evaluated in this study. Another goal of 
this study was to see whether DEXA can detect and quantify bony defects in the femur, 
before hip revision surgery.
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meThodS 
This study consisted of two parts; first part was a cadaver study in which femoral 
specimens from cadaver donors were used to determine bone loss of the femur before hip 
revision and to evaluate steps of hip revision arthroplasty with bone impaction grafting 
with DEXA. Second part of this study was an observational pilot study in which BMD 
of the femurs of 13 patients, 1 to 5 years after hip revision surgery with bone impaction 
grafting, was analysed with DEXA. 
1. Cadaver study
Ten femoral specimens from cadaver donors and 9 femoral heads from living donors were 
obtained from Bislife (Leiden, The Netherlands). All donors or family of the donors had 
given permission for donation and transplantation-related research. Donors were selected 
and procured according to EU directives for tissue donation [28]. The allograft bone 
appeared not suitable for donation; however the bone was suitable for transplantation-
related research. After donation, tissue was stored at -80°C.
Procedure 
The femoral heads were morselized in order to obtain cancellous bone chips with a 
bone mill (Novio Magus bone mill, Spierings Medical Technology, Nijmegen, The 
Netherlands).
The femurs were thawed; soft tissue was removed and inspected macroscopically for 
pathology. Then a cascade of operations was done. At several steps, 2 DEXA scans were 
made and the femur was weighted.
1. The femoral head was resected from the femur. 
2. An Exeter prosthesis (Stryker Inc., Newbury, UK) was placed in the 
proximal femur using standard instruments. 
3. A segmentaldefect was created around the calcar region of the femur, 
since this is the area in which most defects after primary arthroplasty 
are found. All ten femoral specimens had different defect sizes. 
4. The segmental defect in the femoral cortex was covered with a metal 
mesh. 
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5. The femoral canal and the defect were filled with morselized bone 
chips on top of a bone plug, starting most distally and bone impaction 
grafting was done.
6. Bone cement was introduced in the femoral canal and the prosthesis 
was inserted
2. observational pilot study
Thirteen patients with a hip revision surgery for the femoral component or combined 
femoral/acetabular revision with bone impaction grafting and fixation with cement during 
the last 5 years at Reinier de Graaf Hospital in Delft, The Netherlands were included in 
this study. This study was approved by the local Medical Ethics Committee. All patients 
signed an informed consent before participating in the study. 
Procedure
All patients received a DEXA scan of the revised hip, the contralateral side and of the lumbar 
spine. To assess the reproducibility of the measurements, all scans were performed twice, 
on the same occasion, after being repositioned on the scan table. All DEXA scans were 
made by one person. The patients were positioned supine on the scan table with the knee of 
the leg to be scanned supported on a foam positioner. During the DEXA examination the 
foot of the treated leg was place in a triangular support in 25 degrees of internal rotation. 
Oxford Hip Score (OHS) and Hip disability and Osteoarthritis Outcome Score (HOOS) 
were scored to evaluate clinical outcomes. 
All DEXA scans in both parts of the study were made with a QDR-4500 bot densitometer 
(Hologic Inc, Bedford, MA, USA) and scans were analyzed using the 7 zones of Gruen 
[29] (Figure 7.1). Cement was included during DEXA analysis [17]. All measurements 
were done by the same person. 
Statistics
Spearman’s Rho was used to determine the relation between the weight-differences of 
the femur after the defect was created and the corresponding differences in BMD and 
BMC. Spearman’s Rho was also used to calculate the relation between OHS and HOOS. 
Repeatability was calculated using Cronbach’s alpha.
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All statistical analyses were performed using IBM SPSS statistics 20.0 (Chicago, Illinois). 
Differences were considered to be significant at p-values <0.05.
ReSuLTS
1. Cadaver study
Results of the femoral BMD of Gruen zone 7 after step 2, 3 and 6 for all 10 femoral spe-
cimens are shown in Figure 7.2. Mean weight of the created defects was 16.8 g (range 
8.5–30.9 g). 
No correlation could be found between the weight of the created defects (measured as the 
difference of the weight of the femur before and after creating the defect) and the BMD- 
or BMC-differences in Gruen zone 7 (p=0.20 and p=0.28, respectively). Moreover, no 
Figure 7.1 Zones of Gruen in a DEXA image of the cadaver study.  
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correlation between the weight of the created defects and the BMD- or BMC-differences 
in Gruen zone 1 was found (p=0.60 and p=0.93 respectively). 
The influence of a mesh is shown in Figure 7.3. For all gruen zones, the mean BMD 
difference of the femur with and without a defect (BMD after step 3 minus BMD after 
step 2) is shown and compared to the mean BMD difference when a mesh is included 
(BMD after step 4 minus BMD after step 2).
Repeatability for all DEXA scans was 1.0 and 0.99 for BMC and BMD respectively. 
2. observational pilot study
Thirteen patients, with revision surgery of the hip in combination with bone impaction 
grafting, matched our criteria. After performing all DEXA scans, one patient was excluded 
since it was impossible to visualize the bone on the DEXA scan due to the amount of 
meshes and cerclage wires used during the operation. Therefore 12 patients were used 
Figure 7.2 BMD after step 2, 3 and 6 for ROI 7 for all femoral specimens. Step 2: Femur with 
prosthesis, step 3: Femur with prosthesis and a defect in the calcar region of the femur. Step 6: 
Femur at the end of the revision with mesh, bone impaction grafting and cement.  
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for evaluation. Mean age was 71.9 (±9.5) years. Range of the postoperative scan intervals 
was 10–63 months after surgery. 
The average BMD of the revised hip was higher when compared to the BMD of the 
contralateral side. This could not be statistically confirmed since only 12 patients were 
analyzed (Figure 7.4). 
ICC was 0.923 for all first and second DEXA scans of the revised hip. When results of 
individuals with cerclage wires and meshes are excluded, the repeatability of the BMD of 
the revised hip increased to 0.955. Contrary, when only the results of BMD of individuals 
with cerclage wires and meshes are analyzed, repeatability dropped to 0.796.
Mean results of the OHS were 36.1 (±12.7). Mean HOOS results were 65.8 (±23), 62.5 
(±23), 63.1 (±28), 39.0 (±34) and 37.0 (±32) for subscales pain, symptoms, activity of 
daily living, sport and recreation function and hip related quality of life respectively.     
Figure 7.3 Mean results of BMD all femora of the cadaver study for all gruen zones, influence 
of mesh on BMD. The blue line represents the mean BMD difference of the femur with and 
without a defect (BMD after step 3 minus BMD after step 2). The red line represents the mean 
BMD difference when a mesh is included (BMD after step 4 minus BMD after step 2). 
 
‐0,6
‐0,4
‐0,2
0
0,2
0,4
0,6
0,8
1
1 2 3 4 5 6 7
B
M
D
 d
if
fe
re
nc
e
Gruen zones
109
D
EXA and hip revision surgery
Chapter 7
dISCuSSIon
This study evaluated DEXA for the quantification of bony defects in the femur and bone 
remodeling after hip revision surgery with BIG. 
First, a cadaver study was performed. Results showed that the defects created in the femur, 
in Gruen zone 7, could not be quantified at the DEXA scans. Contrary, Laursen et al. [26] 
performed a cadaver study in which the defects created in the acetabulum correlated good 
between the BMC differences measured and the corresponding ash weights of the bone 
retrieved from the acetabulum. However, their created defects were more standardized 
when compared to the defects created in our cadaver study. 
Results from the cadaver study showed that meshes have a great influence and that the 
same bone defect, covered with a mesh, results in a totally different BMD and BMC. 
When the results of the observational pilot study in humans are analyzed, the influence 
of a mesh on BMD is also shown here. The repeatability of BMD-measurements with 
DEXA of revised femurs with mesh is greatly reduced when compared to the repeatability 
of BMD-measurements with DEXA of revised femurs without mesh. Karrholm et al. 
Figure 7.4 Mean BMD of the observational pilot study of the 7 Gruen zones of the revised 
side (blue line) and the contralateral side (red line).                                        
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[30] performed BMD measurements with DEXA after hip revision surgery with BIG 
and cement for fixation of the femoral component. They were able to show an increased 
BMD in most Gruen-zones postoperatively, however they did not use a mesh to cover 
the defect. Lamberton et al. [1] showed that they used cerclage wiring in more than 50% 
of all hip revision surgeries with BIG for femoral reinforcement and that a mesh is used 
in more than 9% of all surgeries. 
Conclusion
Since cerclage wiring and meshes are frequently used during femoral revision with BIG, 
DEXA might not be suitable to monitor BMD after femoral revision surgery with BIG.
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Hip revision arthroplasties are surgical challenging and costly procedures [1]. Restoration 
of the bone stock deficiency after removal of the primary implant is one of the major 
problems during the revision procedure. With the bone impaction grafting (BIG) 
technique the surgeon is able to restore the bony defects in acetabulum and/or femur 
[2]. Results of BIG are good, but survival rates of the implant after revision surgery with 
BIG are lower when compared to primary THAs [2-9]. This thesis focused on BIG and 
how in future the results of hip revision surgery with BIG could be improved by the 
addition of anti-resorptive drugs and antibiotics to the allograft bone chips which are 
used during impaction grafting.  
Loosening and hip revision surgery
Irrespective to the use of BIG, the incidence of loosening of the prosthesis after hip 
revision surgery after 2 to 20 years is 19 to 30% of all failures [10-13]. In case of the use 
of BIG an imbalance between resorption of bone by osteoclasts and formation of new 
bone by osteoblasts might contribute to early migration and eventually lead to revision 
of the prosthesis because of loosening. Early migration of stems in hip revision surgery 
with BIG might be prevented by impregnation of allograft bone with bisphosphonates. 
In chapter 3 the results of different locally applied bisphosphonate concentrations in a 
goat bone chamber model are presented. We concluded that there is a dose-response 
relation for local application of alendronate with respect to the amount of new bone as 
well as the amount of non-resorbed bone graft remaining in the bone chamber 12 weeks 
after implantation. At the optimum dose of 1 mg/mL, the amount of allograft resorption 
was rather high, but the amount of new bone was high as well, leading to a mixture of 
graft and new bone with a very high density in the chamber. At a dose of 2 mg/mL, the 
amount of new bone was less when compared to 1 mg/mL, while resorption percentages 
appeared to decrease strongly. It has been observed in other studies that by increasing 
the bisphosphonate concentration, bone metabolism can be blocked completely which 
might result in decreased implant fixation [14]. It is therefore crucial to have an optimal 
concentration of the locally applied bisphosphonate leading to a good mix of allograft 
bone and new bone, which is responsible for fixation strength. 
There are several possible explanations for the increase of new bone after 12 weeks in 
the bisphosphonate groups compared to the control groups. First, the bone present in 
the bone chamber after 12 weeks is the net result of bone formation and bone resorption 
during the implantation period. The newly formed bone in the control groups is likely to 
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be resorbed rapidly again by osteoclasts in this model, which yields a net low amount of 
new bone after 12 weeks. This has been observed in various other experiments with the 
same bone chamber model as used in the study of this thesis. Secondly, it was proposed 
by Jakobsen et al. [15] that the increase in new bone in the bisphosphonate groups might 
be explained by the prolonged osteoconductive effect of the allograft. Third, in addition to 
the well described action of bisphosphonates on the inhibition of osteoclasts, it has been 
demonstrated that administration of particular types of bisphosphonate might stimulate 
the proliferation of mesenchymal stem cells under certain conditions [16]. Such anabolic 
effect of (different) bisphosphonates on bone formation is suggested in several in vitro 
[17-21] as well as in one in vivo study [22].
In contrast to an increase of new bone after local application of bisphosphonate, at high 
doses the bisphosphonate might be toxic for osteoblasts and act as a catabolic factor for 
bone formation, with inhibition of new bone as a result [20, 23]. One explanation for 
the low amount of new bone formation might be explained by the experimental setup. 
Allograft bone, impregnated with bisphosphonates, is in several animal studies tested in 
bone conduction chambers. These bone conduction chambers are very small and totally 
filled with allograft bone before implantation. If the allograft bone is not resorbed due 
to the high bisphosphonate concentration, no room is available for new bone formation 
in the bone conduction chamber. Another explanation for the low amount of new 
bone formation at high bisphosphonate concentrations might be the toxicity of the 
bisphosphonate on bone tissue. At a high dose, bisphosphonates are toxic to osteoblast, 
which inhibits new bone formation [20, 23].
Several other studies presented results on the local administration of bisphosphonates in 
combination with allograft bone. In chapter 2 an overview of these studies is presented. 
Local administration of bisphosphonates in the optimum concentration might play 
an important role in preventing resorption of the allograft bone by inhibition of the 
osteoclasts. Therefore, local use of bisophosphonates might improve stability after 
surgery in which a prosthesis is combined with allograft bone to restore bony defects. 
However, most of these studies are animal studies. These animal studies differ from the 
human clinical situation. An important difference is that during hip revision surgery with 
BIG in humans, cement is used after impaction of the bone graft chips. This cement is 
pressurized to facilitate cement penetration into the graft. Then, the prosthesis is inserted. 
During the animal studies no bone cement has been used and therefore, the situation 
in the bone conduction chamber is not comparable to the clinical situation. A second 
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difference when the animal studies are compared to the human clinical situation is that 
most animal studies do not use models where the bone graft is loaded. In humans direct 
load transfer will take place through the implant-bone interface. In contrast, the allograft 
bone is placed into a bone conduction chamber without load transfer. Although not many 
studies investigated the effect of load on the incorporation process of allograft bone, it 
was demonstrated that the bone that is formed after non-loaded allograft incorporation is 
less dense then loaded bone graft [24, 25]. Probably the lack of load during incorporation 
might promote resorption, or, more likely load might be a factor needed for the stimulation 
of new bone. Irrespective to the cause, the bone chamber model makes it easier to detect 
potential differences in allograft resorption and new bone formation when bisphosphonate 
impregnated bone chips are compared with normal bone chips [15]. 
There is only one study that we know of, in which local application of bisphosphonates is 
combined with allograft bone and a prosthesis in humans [26]. Results after 24 months 
were good; impregnation of the allograft bone chips with bisphosphonate prevented 
resorption and potentially might reduce the risk of mechanical failure, based on the bone 
mineral density measured with DEXA. This bone mineral density was slightly increased 
in the bisphosphonate group, while the control group showed a decrease in bone mineral 
density. However, long term results are not available yet.
In order to stimulate bone formation, we added demineralized bone matrix (DBM) to the 
allograft bone in the bone chamber study in goats (chapter 3). It was hypothesized that the 
growth factors in the DBM would stimulate osteoblasts. DBM is a product of processed 
allograft bone and contains collagen, proteins and growth factors [27]. According to 
literature, demineralization of bone theoretically facilitates the release of growth factors 
which could increase the bioactivity of the graft and positively influence new bone 
formation and thus the amount of new bone [28, 29]. However, we were not able to find 
any differences between bone formation in the bone chamber with and without DBM in 
goats. Our results confirm the results from several other studies studying the same aspect 
of bone graft incorporation [30, 31]. However, others have demonstrated an enhancing 
effect of DBM on bone formation [32, 33]. Bae et al. [34] evaluated the amount of growth 
factors in different DBM products. They concluded that the quantity of growth factors in 
all DBM products is low. Moreover, the variability of the concentration of growth factors 
among different lots of the same DBM product is higher than the variability among 
different DBM products. They therefore question the efficacy and reliability of DBM. 
One lot of DBM is made from bone of one donor, which might explain the differences 
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in growth factors between different lots. However, in our study we used DBM of bone 
of two different goats and pooled these before use. With pooling, we reduced the risk 
that the lack of increasing bone formation in the DBM groups could be explained by 
the differences in BMP-concentration among different lots. However, pooling of bone 
of two different goats might not be enough, since theoretically both lots might have low 
amounts of growth factors. 
An important reason for the lack of effect of the DBM might have been that the content 
of growth factors was similar to that in the non-decalcified allograft bone particles. In our 
bone chamber model the histology showed that the mix of decalcified bone and allograft 
bone was both resorbed at constant speed. If growth factors would be released during 
resorption of the graft (irrespective to the demineralization) no effect of DBM could be 
expected under these experimental conditions.  
Future perspectives of loosening and hip revision
Based on the increasing number of primary hip surgeries, the number of hip revision 
surgeries is expected to increase [12], and therefore, BIG might be applied more frequently 
in the future. Understanding the challenges and the variables affecting the outcome of 
BIG is therefore of great importance. 
According to Garcia-Cimbrelo et al. [35], clinical outcome according to the Merle 
D’Aubigné and Postal score after hip revision surgery with BIG was less successful 
and subsidence was significantly greater in patients with major bone defects. This is 
in accordance to the results of Ten Have et al. [9] and of Nelissen et al. [36]; extensive 
subsidence after BIG occurred mainly in patients with grade IV Endo-Klinik-classified 
defects (Table 8.1). Gokhale et al. [37] identified prognostic factors for stem and cup 
Table 8.1 Endo-Klinik classification of defects [93]
Grade I Radiolucent lines confined to the upper half of the cement mantle; clinical signs of 
loosening
Grade II Generalized radiolucent zones and endosteal erosion of the upper femur leading to 
widening of the medullary cavity
Grade III Widening of the medullary cavity by expansion of the upper femur
Grade IV Gross destruction of the upper third of the femur with involvement of the middle third, 
precluding the insertion of even a long-stemmed prosthesis
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migration after BIG to restore bone stock in hip revision surgery. They concluded that 
migration occurred mainly during the first 3 months after surgery. Age, femoral diameter, 
stem design and density of the graft at the tip of the stem were variables explaining changes 
in stem alignment. The initial stability of the graft is correlated to the number of impaction 
blows performed onto the graft [9]. Moreover, the size of the bone graft also determines 
stability; large grafts might remodel less, resulting in collapse of the graft and possible 
subsidence [9]. It is unclear what the effect of early weight bearing after surgery is; no 
differences in migration pattern could be observed between restricted and unrestricted 
weight bearing after hip revision arthroplasty [38]. 
If possible predisposing factors for early migration after hip revision surgery with BIG 
could be identified in individual patients, an intervention with adding bisphosphonates 
to the bone graft might be prescribed more selectively. However, first the effect of 
adding bisphosphonates to bone grafts on implant fixation and implant stability has 
to be studied. Roentgen stereophotogrammetric analysis (RSA) is a frequently used 
method to measure primary stability of an implant [39]. In RSA, the three-dimensional 
position and orientation of a prosthesis is determined by the reconstruction of the three-
dimensional position of well-defined tantalum markers on the bone and implant. Also, a 
projected contour of a model of the implant is calculated and matched onto the detected 
contour of the actual implant in the RSA radiograph [40]. This way, micromotions of the 
prosthesis with respect to the well-defined markers can be measured. Numerous studies 
on RSA in hip revision surgery with BIG have been performed [36, 38, 41-46]. It was 
concluded that the Exeter femoral stem, a standard implant which is also used in hip 
revision surgery with BIG, showed continued migration. Despite this migration, clinical 
results are good. Nieuwenhuijse et al. [46] studied the long term RSA results of primary 
THA with the Exeter stem. They concluded that RSA might be able to predict long-term 
failure of implants designed to migrate. Therefore, RSA might be an appropriate method 
for studying the impact on migration when bisphosphonate-impregnated allograft 
bone chips are used for BIG. In addition, the clinical outcome of the local application of 
bisphosphonates has to be studied.  
Infection 
By preventing infections, unnecessary deterioration of the quality of life of the patient 
as well as a reduction of health care costs might be achieved. Numerous strategies to 
prevent infection are developed, but the implementation of these measures in clinical 
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practice varies widely [47]. In this thesis, several measures are discussed, as the use of 
pre-processed bone chips, impregnation of allograft bone with antibiotics and behavior 
in the operating theatre. 
Pre-processed bone chips
It was hypothesized in chapter 4 of this thesis that the use of pre-processed bone chips for 
BIG might reduce bacterial contamination during surgery and as a result, decrease the risk 
of infection. However, processing of femoral heads in a clean room does not reduce the 
number of bacteria present on the allograft bone used during the operation. We did not 
find any difference between the cultures of the femoral heads processed during surgery 
and the cultures of the bone chips prepared in the clean room. However, bone chips 
prepared in a clean room before surgery do have several advantages. The preparation 
of the bone chips during surgery is less time consuming compared with the use of pre-
processed bone chips. This time benefit could not be quantified, but is estimated to be 
approximately 10 to 15 minutes for each femoral head to be processed. Moreover, usage 
of pre-processed bone chips might be important since pre-processed bone chips are 
more thoroughly cleaned by rinsing the chips 5 times with saline and thereby washing 
cells and tissues out of the graft and reducing the immunological reaction. This might 
result in a better incorporation of the allograft bone after bone impaction grafting [48]. 
To make a choice between pre-processed bone chips and preparation of bone chips in 
the operating room, these factors, together with the additional costs, must be considered. 
Impregnation of allograft bone with antibiotics
As prophylaxis against infection, bone cements containing antibiotics were developed. These 
cements may serve as a drug delivery system and make it possible to achieve higher local 
drug concentrations. However, there is debate on the efficacy of the antibiotic-containing 
cements [49]. Probably 90% of the antibiotic in the cement will never be released [50]. Only 
when cracks are formed in the cement layer, a small, sub-therapeutic level of antibiotics 
will be released into the surrounding tissue. This type of release can continue for years, 
potentially inducing insufficient bactericidal activity and provide a favorable environment 
for the cultivation of resistant bacterial strains [50]. Hope et al. [51] noted that of thirty-
four patients with joint infection after primary total hip arthroplasty with antibiotic-loaded 
cement, 88% had at least one resistant bacterial strain. In contrast, a review of Dunbar [52] 
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showed that antibiotic bone cement has clear efficacy in reducing infection rates in THA. 
Another preventive measure to reach high local antibiotic concentrations might be the 
impregnation of allograft bone with antibiotics. In chapter 5 we confirmed the results of 
other studies that it is possible to impregnate allograft bone with antibiotics and this way, 
achieve high local concentrations of the antibiotic, which can serve as a prophylaxis against 
infection [53-59]. In addition, we showed that the storage of bone chips impregnated 
with vancomycin or cefazolin at -80˚C does not affect the antibacterial properties. 
Consequently, the antibiotics can be safely added before surgery which is easier and less 
time consuming. When compared to antibiotic containing bone cement, Buttaro et al. [60] 
concluded after studying 57 patients with vancomycin-impregnated allografts to restore 
the bone stock, that the incidence of deep sepsis was similar to that reported with antibiotic 
containing bone cement but without the reported pharmacological disadvantages as the 
release of sub-therapeutic levels of antibiotics.  
Local antibiotic therapy has to meet several requirements; the concentration has to be 
above the minimal inhibitory concentration (MIC) to eradicate bacteria, the concentration 
used should not be cytotoxic to osteoblasts nor to the bone tissue, drug delivery has 
to be controlled in order to ensure that known adverse drug reactions like deafness or 
renal failure are prevented and all of the antibiotics have to be eluted rapidly, especially 
when used as prophylaxis since small, sub-inhibitory amounts can induce resistance. 
For prophylaxis, a concentration above the MIC for at least 8 to 10 hours is enough. 
For therapeutic use, the antibiotic is more effective when the concentration is high and 
effective (above the MIC) for a longer period, preferably for 2-4 weeks since the diffusion 
of the antibiotic into the infected tissues takes time, as does the killing of the bacteria. If 
we look at all these requirements, cefazolin is a good choice for impregnation of allograft 
bone as prophylaxis [61]. The elution profile shows a high initial release with rapid decay 
[56]. After three days, all the cefazolin is eluted from the bone chips. Moreover, cefazolin 
is very effective against Staphylococcus epidermidis and Staphylococcus aureus, the main 
pathogens involved in colonizing biomaterials [62]. Vancomycin is another good choice 
for the impregnation of allograft bone chips. The elution profile is not as steep as that 
of cefazolin, however vancomycin has low resistance and allergy rate and is also very 
effective against the pathogens mentioned earlier. 
To determine the antibiotic content of the bone chips after impregnation, a dose-response 
curve for allograft bone impregnated with cefazolin and vancomycin was presented in 
chapter 5. Moreover, in chapter 3 it was concluded that local use of cefazolin in a high 
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concentration (a concentration that appeared well above the MIC for S. epidermidis in the 
dose-response curve) does not affect bone remodeling in a goat model. The amount of 
new bone as well as the amount of graft bone present after 12 weeks was comparable to the 
amount in the control group, without cefazolin. These results confirm the results of Buttaro 
et al. [63]. They histologically analysed vacomycin impregnated bone allografts in two 
hips performed 14 and 20 months after revision surgery with BIG. It was concluded that 
the histological findings were similar to those reported in allografts without vancomycin 
and that high levels of vancomycin did not affect the incorporation of the bone graft. 
The operating theatre
Microbiological contamination of air in the operating room is generally considered to 
be an important risk factor for infection. By monitoring the air in operating theatres, the 
quality of the air can be evaluated. In chapter 6 we evaluated the air quality during 70 hip 
revision surgeries. It was hypothesized that with decreasing the number of door-openings, 
the air quality measured by the number of CFU/m3 also decreases, which might lead to 
a decrease in the infection risk. We did not find a significant association between door-
openings and CFU/m3 in our study (p=0.08). However, the odds ratio of door-openings/
hour after multivariate analysis was 0.14 (0.02–1.24), meaning that if the number of door-
openings/hour increases to more than 4.5, the risk of a number of CFU/m3 of more than 
20 (the HISWPICOT criterion) increases with 7 (1/0.14). The number of surgeries was 
probably not high enough to detect a significant relation. Moreover, the 95% CI of the 
odds ratio of door-openings/hour varied greatly, probably because the results of CFU/
m3 varied throughout the surgeries performed. This variation in CFU/m3 between the 
different surgeries is in accordance with the results of previous reports [64, 65].  
The number of door-openings was very low during the surgeries since doors were only 
allowed to be opened if strictly necessary. When the number of door-openings/hour is 
compared to the number of door-openings/hour in other studies, we can confirm that 
our frequency of door-opening is very low [64, 66-71]. Our results confirm the results 
of other authors who also reported no significant contribution of door-openings to the 
number of CFUs/m3 at the operating room [65, 72]. Contrary, a positive relation was 
found in several other studies [73-75]. The positive relation between door-openings and 
the number of CFUs/m3 might be explained by the turbulent airflow out of the operating 
room when the operating room door is open. This results in an operating room supplied 
with unfiltered outdoor air and an increase in microbial contamination [73]. 
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We were not able to show a correlation between number of CFU/m3, particles and CFU/
m2/hour on the sedimentation plate. These results confirm the results of several other 
studies [76, 77], although some authors did find a significant correlation [78]. Different 
variables are measured with the different methods: sedimentation plates are used for 
passive sampling and might provide best insight in the number of bacteria settling on 
surfaces, volumetric sampling of the number of CFU/m3 is active sampling to obtain 
information on the number of bacteria in the air, while particle measurements (active 
sampling) provides information on the number of dust particles in the operating room. 
This might explain the varying results, since these variables might differ throughout the 
hospitals or even throughout the same operating room since different factors influence 
the results, as the frequency of door-opening [78, 79]. At this moment no international 
consensus on what method to be used for routine air monitoring is available [73]; there 
is still debate on the sampling techniques to be used, their frequency of application and 
even on the usefulness of such checks and controls. International standards offer different 
techniques (active through air samplers or passive sampling through sedimentation plates) 
and different kinds of samplers, thus leaving the choice of system open [78]. 
According to Andersson et al. [80], the duration of the surgery is of clinical relevance since 
the total CFU level increases with increasing duration of the surgery, thereby exposing 
the wound to an increased total number of CFUs and as a consequence increasing the 
risk of infection. This result was confirmed by Ong et al. [81]. However, we were not 
able to show an association between the numbers of CFU and the operation time. In 
addition, no relation between the number of people present at the operating theatre and 
the number of CFU at the operating theatre could be found. 
Future perspectives of infection and hip revision surgery
The etiology of infection is multifactorial. Identifying risk factors for the individual patient 
and optimizing medical management of the conditions seems therefore important [82]. 
Pulido et al. [83] identified several risk factors for the development of a periprosthetic 
joint infection; patient related factors included a BMI of more than 40 kg/m2, an 
Amercian Society Of anesthesiologists score (ASA) of more than 2 and postoperative 
atrial fibrillation, myocardial infarction and urinary tract infection. The influence of 
preexisting comorbidities on periprosthetic joint infection was confirmed by Ong et al. 
[81]. Bozic et al. [82] further specified these preexisting comorbidities. They concluded 
that rheumatologic disease, obesity, coagulopathy and preoperative anemia were 
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associated with an increased risk of periprosthetic joint infection. Moreover, Malinzak et 
al. [84] also stated that patient comorbidities as obesity and diabetes significantly affect 
the infection risk. The information from these studies is important to consider when 
discussing the risks associated with total hip arthroplasty in patients with preexisting 
comorbidities. Medical management of these conditions should be optimized prior to 
considering elective total hip arthroplasty in this patient population [82]. 
Usage of antibiotic-impregnated allograft bone for BIG might be a good option for 
prophylaxis. When we take a close look at the requirements for local antibiotic prophylaxis, 
we can conclude that the impregnation of bone allograft with cefazolin or vancomycin 
meets those requirements and that it might be a good alternative for bone cement to 
achieve high local antibiotic concentrations. However, it is likely that it will only be a 
matter of time before bacteria develop a mechanism of resistance against any new locally 
applied antibiotic. Therefore, further research into the use of combinations of antibiotics, 
i.e. multidrug targeting, has to be performed [85].
Imaging of bone remodeling
Since the introduction of BIG, there has been a debate whether the impacted bone 
graft actually integrates into the surrounding host bone. Biopsies obtained from the 
impacted area have suggested that the allograft is in time replaced with new bone [86, 
87]. Although clinical radiographs also provide some evidence for re-trabeculation and 
thus incorporation of the graft, reliable information regarding the amount of incorporated 
allograft is missing. In chapter 7 of this thesis we evaluated DEXA for the quantification 
of bone remodeling after hip revision surgery with BIG. It was concluded that the use of 
meshes to reconstruct the defect in combination with BIG, makes DEXA less reproducible 
and therefore not usable. 
Future perspectives of imaging of bone remodelling
Since obtaining biopsies can compromise the healing and introduces a risk of infection or 
fracture, a method other than DEXA for documenting the healing process of the allograft 
bone has to be studied. Positron emission tomography (PET) showed to be a sensitive 
method for evaluating neovascularistion and bone formation in impacted morsellized 
allografts [88, 89]. It was concluded that after 6 years, the metabolism of the allografted 
bone had normalized compared to native bone. Although not studied in revised hips with 
124
General discussionChapter 8
BIG, PET/CT might even be a better method to determine metabolic bone responses 
[90]. Bone scintigraphy might be another possibility to study new bone formation in a 
non-invasive way. The use of bone scintigraphy was evaluated by Tokgozoglu et al. [91] 
and Hisatome et al. [92]. Both studies showed an intense radionuclide uptake in the area 
corresponding to the graft material, which might be an indicator of new bone formation 
and revascularization of the allograft. Therefore, bone scintigraphy might be suitable for 
gaining insight in the process of remodeling of the allograft bone in BIG. 
General conclusion
It can be concluded that there is a dose-response relation for local application of 
alendronate with respect to the amount of new bone as well as the amount of non-
resorbed bone graft. Therefore, local administration of bisphosphonates in the optimum 
concentration might play an important role in improving stability after surgery in which a 
prosthesis is combined with allograft bone to restore bony defects. If possible predisposing 
factors for early migration after hip revision surgery with BIG could be identified in the 
individual patient, local application of bisphosphonates should be applied selectively. 
However, more research has to be done to study the effect of local use in patients.
Impregnation of allograft bone with antibiotics can be used to reach efficient high local 
antibiotic concentrations and serve as a prophylaxis against infection. Pre-processed 
bone chips for BIG have similar levels of microbiological contamination when compared 
to femoral heads morselized during surgery, however pre-processed bone chips will be 
incorporated better and they are more easily used during surgery. 
The frequency of door-openings during surgery is correlated to the microbiological 
contamination (CFU/m3) of the operating room. Therefore, to prevent infection, door-
openings during surgery should be kept at a minimum. The duration of the surgery and 
the number of people present during surgery were not correlated to the microbiological 
contamination during surgery. 
The use of meshes to reconstruct a defect during BIG ensures a DEXA scan less 
reproducible. For the quantification of bone remodeling after hip revision surgery with 
BIG, another method has to be used. 
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Mechanical loosening is one of the most common causes of failure of a primary total hip 
arthroplasty (THA) and occurs secondary to a chronic, granulomatous, inflammatory 
response that is stimulated and maintained by implant-derived wear particles. This process 
is complex and might lead to a localized or systemic reduction in bone mass. After failure 
of a primary THA, a more challenging and costly hip revision surgery is needed. One of 
the techniques to restore the bone stock around the implant during hip revision surgery 
is bone impaction grafting (BIG). With BIG, first, bony defects in acetabulum and femur 
can be restored with metal meshes in order to recreate a contained defect. Next, these 
defects are filled with tightly impacted morselized allograft cancellous bone chips in 
combination with a cemented new prosthesis. The allograft bone serves as a scaffold; new 
blood vessels and woven bone can grow into the allograft bone and during this process the 
allograft bone is resorbed by osteoclasts. Remodelling of the newly formed immature bone 
into its characteristic mature bony structure will lead to a biological repair of the defect. 
This thesis focused on BIG and how in the future the results of hip revision surgery with 
BIG could be improved by treatment of the allograft bone chips which are used during 
impaction grafting.  
loosening and hip revision surgery
Nineteen to thirty percent of all failures after revision surgery are caused by loosening 
of the prosthesis. When allograft or autograft bone tissue is being used, the coupling 
between osteoblast and osteoclast function is less organized. Therefore it might lead 
to faster resorption in relation to bone deposition. In the case of BIG this may lead to 
destabilization of the implant. This mechanical weakness might result in loosening of 
the prosthesis. To optimize the balance between bone resorption and bone formation 
bisphosphonates might be used. 
Several studies have been performed on the local application of bisphosphonates in 
combination with allograft bone, however results vary greatly. An overview of all studies 
combining bisphosphonates with allograft bone is presented in chapter 2 of this thesis. 
Local administration of bisphosphonates in the optimum concentration might play 
an important role in preventing resorption of the allograft bone by inhibition of the 
osteoclasts. Therefore, local use of bisophosphonates might improve stability after surgery 
in which a prosthesis is combined with allograft bone to restore bony defects.
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In chapter 3 the results of a bone chamber study in goats are presented. We conclude 
that there is a dose-response relation for local application of alendronate with respect 
to the amount of new bone as well as the amount of non-resorbed bone graft remaining 
in the bone chamber 12 weeks after implantation. In order to stimulate bone formation, 
we also added DBM to the allograft bone. It was hypothesized that the growth factors in 
the DBM would stimulate osteoblasts. However, we were not able to find any differences 
between bone formation in the bone chamber with and without DBM in goats.
infection and hip revision surgery
Nowadays, infections occur in approximately 0.5 to 3% of all primary THAs and after 
revision THA, these percentages are higher and range from 4 to 6%. Infection is a 
potentially devastating complication; patients may require further surgery, additional 
nursing care and in extreme cases it is followed by the death of the patient. Reducing the 
risk of infection is a major challenge that deserves continued attention. It is important 
to understand etiology and risk factors for infection to be able to prevent and reduce 
infection rates. 
The use of allograft bone chips for BIG introduces a potential source of infection. In 
most cases, the allograft bone which is used for BIG, is prepared in the operating theatre 
during surgery just prior to use. The preparation of bone chips in the operation room 
takes about ten minutes, it necessitates the use of special instrument such as a bone mill 
and due to the limited area in a down flow plenum system, an enclosed space inside the 
operating theatre with laminar air flow, the preparation of bone chips often takes place 
outside the plenum. However, the processing of these femoral heads can also be done in 
the laboratory of a bone bank. In that case the femoral heads are prepared in a top-class 
level clean room with optimal controlled environmental conditions and no surgery time 
is needed for preparation. In chapter 4, we conclude that processing of femoral heads 
in a clean room does not reduce the number of bacteria present on the allograft bone 
used during the operation. We did not find any difference between the cultures of the 
femoral heads processed during surgery and the cultures of the bone chips prepared in 
the laboratory. 
Several studies have shown that the allograft bone, used for BIG, can act as a carrier for 
antibiotics, either by impregnating the bone grafts with various antibiotic solutions or 
by mixing them with antibiotic powders. In chapter 5 we confirmed the results of these 
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studies that it is possible to impregnate allograft bone with antibiotics and this way, 
achieve high local concentrations of the antibiotic, which can serve as a prophylaxis 
against infection. Moreover, we showed that the storage of bone chips impregnated 
with vancomycin or cefazolin at -80˚C does not affect the antibacterial properties. 
Consequently, the antibiotics can be safely added before surgery which is easier and less 
time consuming.
To determine the antibiotic content of the bone chips after impregnation, a dose-response 
curve for allograft bone impregnated with cefazolin and vancomycin was presented 
in chapter 5. Moreover, in chapter 3 it was concluded that local use of cefazolin in a 
high concentration (a concentration that appeared well above the Minimal Inhibitory 
Concentration (MIC) for S. epidermidis in the dose-response curve) does not affect 
bone remodeling in a goat model. The amount of new bone as well as the amount of 
graft bone present after 12 weeks was comparable to the amount in the control group, 
without cefazolin.
In chapter 6 we evaluated the air quality during 70 hip revision surgeries since prosthesis 
infection is often caused by bacterial contamination intra-operatively. It was hypothesized 
that with decreasing the number of door-openings, the air quality measured by the number 
of CFU/m3 also decreases, which might lead to a decrease in the infection risk. We were 
not able to show a significant relation between these variables (p=0.08), probably because 
the number of surgeries was not high enough to detect a significant relation and because 
the number of door-openings was already very low during the surgeries since doors were 
only allowed to be opened if strictly necessary. Moreover, no relation between surgery 
time or the number of people present during surgery and the number of CFU/m3 could 
be found. We were not able to show a correlation between number of CFU/m3, particles 
and CFU/m2/hour on the sedimentation plate.
Since early visualization of increased bone resorption might be of importance for early 
diagnosis of bone loss, Dual-Energy X-ray Absorptiometry (DEXA) might be a tool for 
quantification of changes in bone content and bone remodeling after hip revision surgery 
with BIG. Therefore, in chapter 7 DEXA was evaluated for the quantification of bone 
remodeling after hip revision surgery with BIG. However, it was concluded that the use 
of meshes to reconstruct the defect in combination with BIG ensures a DEXA scan less 
reproducible. For the quantification of bone remodeling after hip revision surgery with 
BIG, another method has to be used.
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Mechanische loslating is een van de meest voorkomende oorzaken van loslating van 
een primaire totale heupprothese (THP). Mechanische loslating ontstaat secundair aan 
een chronische, granulomateuze en inflammatoire respons. Deze wordt gestimuleerd en 
onderhouden door deeltjes die van het implantaat afkomstig zijn. Dit proces is complex 
en kan leiden tot een lokale of totale daling van de botmassa. 
Na loslating van een primaire THP is een meer uitdagende heuprevisieoperatie nodig. 
Een van de technieken om de hoeveelheid bot rondom het implantaat te herstellen tijdens 
deze operatie is ‘bone impaction grafting’ (BIG). Met BIG worden eerst de botdefecten 
in het acetabulum en/of de femur hersteld met een metalen mesh, waarna deze defecten 
worden opgevuld met stevig geïmpacteerde gemalen allograft botchips in combinatie met 
een gecementeerde prothese. Het allograft bot fungeert als een steiger; nieuwe bloed-
vaten en bot kunnen in het allograft bot groeien. Tijdens dit proces wordt het allograft 
bot geresorbeerd door osteoclasten. Remodellering van het nieuw gevormde bot naar 
de karakteristieke volwassen botstructuur leidt tot het biologische herstel van het defect. 
In dit proefschrift wordt behandeld hoe in de toekomst de resultaten van heuprevisie-
operaties met BIG verbeterd kunnen worden door het behandelen van de botchips die 
gebruikt worden tijdens de impactie. 
loslating en heuprevisieoperaties
Negentien tot dertig procent van het falen van protheses na een heuprevisieoperatie wordt 
veroorzaakt door loslating van de prothese. Indien er gebruik is gemaakt van allograft of 
autograft botweefsel tijdens de revisieoperatie, is de koppeling tussen osteoblast- en osteo-
clastfunctie minder goed. Hierdoor kan de botresorptie sneller zijn dan de botaanmaak. 
In het geval van BIG kan dit leiden tot een instabiel implantaat. Deze mechanische zwakte 
kan leiden tot loslating van de prothese. Om de balans tussen resorptie en aanmaak te 
optimaliseren, kunnen bisfosfonaten een rol spelen. 
Er zijn verschillende studies uitgevoerd waarin het lokaal toedienen van bisfosfonaten 
in combinatie met allograft bot is onderzocht, maar de resultaten hiervan variëren sterk. 
Een overzicht van de studies die bisfosfonaten met allograft bot combineren is gegeven in 
hoofdstuk 2 van dit proefschrift. Het lokaal toedienen van bisfosfonaten in een optimale 
concentratie kan een belangrijke rol spelen in de preventie van resorptie van het allograft 
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bot door inhibitie van de osteoclasten. Mogelijk zorgt dit voor een grotere stabiliteit na 
een operatie waarbij een prothese is gecombineerd met allograft bot om een botdefect 
te herstellen. 
In hoofdstuk 3 van dit proefschrift worden de resultaten van een botkamerstudie in geiten 
gepresenteerd. Geconcludeerd kan worden dat er een dosis-responsrelatie is tussen de 
lokale toediening van alendronaat en zowel de hoeveelheid nieuw bot als de hoeveelheid 
niet geresorbeerd bot achtergebleven in de botkamer 12 weken na de implantatie. Om 
de botformatie te stimuleren werd gedemineraliseerd bot (DBM) toegevoegd aan het 
allograft bot, maar er werd geen verschil gevonden in botaanmaak tussen allograft bot 
met DBM en zonder DBM. 
infectie en heuprevisieoperaties 
In ongeveer 0.5–3% van alle primaire THP’s komen infecties voor. Na revisie-THP zijn deze 
getallen hoger en variëren tussen de 4 en 6%. Infectie kan een zeer ernstige complicatie 
zijn; patiënten hebben mogelijk meerdere operaties nodig, alsmede extra verpleegkundige 
hulp. In extreme gevallen resulteert het in het overlijden van de patiënt. Het verlagen van 
het infectierisico is een grote uitdaging. Het is belangrijk om het ontstaan en de risicofac-
toren voor infectie te begrijpen om in staat te zijn tot preventie van dergelijke infecties. 
Het gebruik van allograft botchips voor BIG introduceert een mogelijke bron van infectie. 
In de meeste gevallen wordt het allograft bot wat gebruikt wordt voor BIG bewerkt op 
de operatiekamer tijdens de operatie. Het bewerken van het allograft bot in de operatie-
kamer neemt ongeveer 10 minuten in beslag en het vraagt om het gebruik van speciale 
instrumentaria zoals het gebruik van een botmolen. Door het kleine oppervlakte van het 
plenum, een ruimte op de operatiekamer met laminaire flow, worden de botchips vaak 
bereid buiten het plenum. Maar het bewerken van de heupkoppen die gebruikt worden 
voor BIG, kan ook gedaan worden in het laboratorium van een botbank. In dat geval 
worden de heupkoppen gemalen en schoongemaakt in een clean room met optimaal ge-
controleerde omgevingscondities. Ook is er geen extra tijd nodig tijdens de operatie voor 
het bereiden van de botchips. In hoofdstuk 4, concluderen we dat, ondanks de verwachte 
voordelen van het bewerken van heupkoppen in een clean room, het aantal bacteriën 
dat aanwezig is op het allograft bot tijdens een heuprevisieoperatie niet vermindert. We 
vonden geen verschil in de bacteriekweken van heupkoppen die bewerkt werden tijdens 
de operatie en de bacteriekweken van de botchips bereid in het labotatorium. 
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Verschillende studies hebben aangetoond dat allograft bot dat wordt gebruikt voor BIG, 
kan dienen als drager van antibiotica, door het impregneren van de botgrafts met verschil-
lende antibiotische oplossingen of door het mixen van de botgraft met antibioticapoeder. 
In hoofdstuk 5 bevestigen we dat het mogelijk is allograft bot te impregneren met antibi-
otica en op deze manier hoge lokale concentraties te bereiken met het antibioticum, zodat 
het kan dienen als een profylaxe tegen infectie. Tevens hebben we aangetoond dat opslag 
van met vancomycine of cefazoline geïmpregneerde botchips bij -80˚C de bactericide 
eigenschappen van het antibioticum niet aantast. 
Om de hoeveelheid antibiotica te bepalen op de botchips na impregnatie, hebben we een 
dosis-responscurve gemaakt voor allograft bot met cefazoline en vancomycine (hoofdstuk 
5). Daarnaast concluderen we in hoofdstuk 3 dat lokaal gebruik van cefazoline in een hoge 
concentratie (een concentratie ruim boven de Minimaal Inhiberende Concentratie (MIC) 
voor S. epidermidis in de dosis-responscurve) geen effect heeft op de botremodellering in 
een geitenmodel. Zowel de hoeveelheid nieuw bot als de hoeveelheid graft bot aanwezig 
in de botkamer na 12 weken was vergelijkbaar met de controlegroep (zonder cefazoline).
In hoofdstuk 6 werd de luchtkwaliteit gedurende 70 heuprevisieoperaties geëvalueerd, 
omdat infectie van de prothese vaak wordt veroorzaakt door contaminatie met bacteriën 
tijdens de operatie. De hypothese was dat met daling van het aantal deuropeningen, het 
aantal bacteriën per m3 (CFU/m3) ook zou dalen, wat zou kunnen leiden tot een daling van 
het infectierisico. We hebben geen significate relatie tussen deze beiden variabelen kunnen 
aantonen (p=0.08), waarschijnlijk doordat het aantal operaties niet groot genoeg was om tot 
significante resultaten te komen. Daarnaast was het aantal deuropeningen al heel laag tijdens 
de operaties omdat de deuren alleen geopend mochten worden indien strikt noodzakelijk. 
Ook vonden we geen relatie tussen het aantal personen aanwezig tijdens de operatie en het 
aantal bacterien per m3. Er werd geen relatie gevonden tussen de deeltjes gemeten tijdens 
de operatie, de hoeveelheid bacteriën op een sedimentatieplaat en de CFU/m3. 
Vroege visualisatie van de stijging van botresorptie na een heuprevisie met BIG zou 
belangrijk kunnen zijn voor snelle diagnose van botverlies. Dual-Energy X-ray Absorp-
tiometry (DEXA) meet de botdichtheid en zou een goede methode kunnen zijn voor het 
zichtbaar maken van veranderingen in hoeveelheid bot en botremodellering. Het gebruik 
van DEXA voor het inzichtelijk maken van botremodellering na een heuprevisieoperatie 
met BIG werd in hoofdstuk 7 geëvalueerd. Uit deze studie concluderen we dat, door het 
gebruik van een mesh om het defect te reconstueren tijdens de opeatie, een DEXA-scan 
niet geschikt is voor de kwantificering van botremodellering na een heuprevisieoperatie. 
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